EP2928919A2 - Protéines de liaison à double spécificité pénétrant la barrière hémato-encéphalique (bbb) - Google Patents

Protéines de liaison à double spécificité pénétrant la barrière hémato-encéphalique (bbb)

Info

Publication number
EP2928919A2
EP2928919A2 EP13812312.0A EP13812312A EP2928919A2 EP 2928919 A2 EP2928919 A2 EP 2928919A2 EP 13812312 A EP13812312 A EP 13812312A EP 2928919 A2 EP2928919 A2 EP 2928919A2
Authority
EP
European Patent Office
Prior art keywords
binding protein
seq
amino acid
group
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13812312.0A
Other languages
German (de)
English (en)
Inventor
Denise Karaoglu HANZATIAN
Tariq Ghayur
Annette J. Schwartz STERMAN
Andrew Goodearl
Maria Cristina HARRIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of EP2928919A2 publication Critical patent/EP2928919A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • BBB BLOOD-BRAIN BARRIER
  • Multivalent and multispecific binding proteins that bind receptors on the Blood-Brain Barrier (BBB), and capable of carrying another brain target domain into the brain, methods of making, in vivo distribution in brain, and their uses in the treatment of acute and chronic neurological diseases, brain cancer, pain are provided.
  • BBB Blood-Brain Barrier
  • the brain prevents the passage of antibodies and other biologic drugs from the blood stream into the brain parenchyma by a highly vascular barrier system referred to as the blood-brain barrier (BBB). Therefore one of the most important factors for successful CNS drug development is the ability to effectively deliver such drugs to the brain.
  • BBB blood-brain barrier
  • the poor distribution of antibody to the brain may be explained, in part, by inefficient convective uptake into the brain (e.g., because of the "tight junctions" in the brain vascular endothelium) and by rapid turnover of brain interstitial fluids, which would correlate with efficient convective elimination of IgG from the brain. As size, shape, lipophilicity and charge etc.
  • BBB blood brain barrier
  • the affinity of the MAb to the receptor is of great importance to ensure dissociation of the MAb after receptor- mediated uptake. Additionally, these receptors show a widespread expression on peripheral organs as well which limits their application for brain-specific delivery. Finally, the molecular weight of the co-transported biologic must be of relatively low molecular weight to ensure uptake. Accordingly, there remains an urgent need for improved BBB delivery technologies, especially with regard to engineered binding proteins of high molecular weight that can penetrate into the brain without disrupting the blood-brain barrier. Such high molecular weight binding proteins include bispecific antibodies and other multivalent and multispecific binding proteins capable of binding two or more antigens (see PCT Publication No. WO 0177342 and US Patent No. 7,612,181 ).
  • HMW binding proteins capable of binding a BBB antigen (e.g., an extracellular receptor, a surface protein, an intracellular receptor, an intracellular protein, a BBB antigen (e.g., an extracellular receptor, a surface protein, an intracellular receptor, an intracellular protein, a BBB antigen (e.g., an extracellular receptor, a surface protein, an intracellular receptor, an intracellular protein, a BBB antigen (e.g., an extracellular receptor, a surface protein, an intracellular receptor, an intracellular protein, a BBB antigen (e.g., an extracellular receptor, a surface protein, an intracellular receptor, an intracellular protein, a BBB antigen (e.g., an extracellular receptor, a surface protein, an intracellular receptor, an intracellular protein, a BBB antigen (e.g., an extracellular receptor, a surface protein, an intracellular receptor, an intracellular protein, a BBB antigen (e.g., an extracellular receptor, a surface protein, an
  • the disclosure provides HMW multivalent binding proteins (e.g., a DVD-lgTM) comprising at least one binding domain or binding site targeting an antigen (e.g., a transport receptor) combined with one or more second binding domains (e.g., variable domains) directed against a therapeutically relevant target.
  • HMW multivalent binding proteins e.g., a DVD-lgTM
  • an antigen e.g., a transport receptor
  • second binding domains e.g., variable domains
  • the binding proteins of the disclosure have one or more binding sites or domains (e.g., one, two, or three binding sites) which are unoccupied upon BBB uptake such that they remain available for binding to the
  • binding sites may be pre-loaded with a therapeutic agent (e.g., an endogenous or exogenous therapeutic protein) to facilitate delivery of the agent to brain.
  • a therapeutic agent e.g., an endogenous or exogenous therapeutic protein
  • the binding proteins of the invention well-suited for the treatment of brain and CNS diseases including, but not limited to, Alzheimer's disease, Parkinson's disease, pain, epilepsy schizophrenia, and brain cancer.
  • the feasibility of systemic delivery of DVD-lgTM to brain tissue has been established by a variety of assays including brain immunohistochemistry.
  • the disclosure provides a dual variable domain (DVD) binding protein that specifically binds to an antigen expressed on brain vascular epithelium of a subject and facilitates uptake of a composition into the brain of the subject.
  • DVD dual variable domain
  • the disclosure provides a binding protein that specifically binds to a receptor expressed on brain vascular epithelium of a subject.
  • the receptor expressed on brain vascular epithelium of a subject is selected from the group consisting of insulin receptor, transferrin receptor, LRP family receptor, melanocortin receptor, nicotinic acetylcholine receptor, VACM-1 receptor, vascular endothelial growth factor receptors 1 , 2 and 3, glucocorticoid receptor, ionotropic glutamate receptor, M3 receptor, aryl hydrocarbon receptor, GLUT-1 , inositol-1 ,4,5-trisphosphate (IP3) receptor, N-methyl-D-aspartate receptor, S1 P1 , P2Y receptor, M6PR, Neuronal nicotinic acetylcholine receptor, Lipoprotein receptor, AchR, DTr, Glutathione transporter, SR-B1 , MYOF, TFRC, ECE1 ,LDLR, PVR, CDC50A, SCARF1 , MRC1 , H
  • LRP family receptors can be chosen from LRP2 or LRP8.
  • the receptor is a transferrin receptor.
  • the binding protein in various embodiments binds the antigen which comprises a target.
  • the target comprises transferrin receptor.
  • the binding protein binds to the antigen with an EC 50 of between 3 and 30 nM.
  • the EC 50 is at least about 3 nM to about 10 nM, about 10 nM to about 15 nM, about 15 nM to about 20 nM, about 20 nM to about 25 nM, or about 25 nM to about 30 nM.
  • the DVD binding protein comprises a DVD-lg.
  • the DVD binding protein is selected from the group consisting of a half-DVD-lg, a scDVD-lg, an fDVD-lg, an rDVD-lg, a pDVD-lg, an mDVD-lg and a coDVD- Ig.
  • the DVD-lg is humanized.
  • the binding protein shows a 1 fold to 10 fold increase in brain concentration in a mammalian subject when administered systemically to the mammalian subject when compared to a second binding protein of the same class as the binding protein that does not specifically bind to a antigen expressed on brain vascular epithelium.
  • the subject is administered intravenously or topically.
  • the binding protein comprises a plurality of binding proteins, for example the binding proteins are located in a mixture, solution, or
  • the binding protein localizes to brain parenchyma or neuronal cell bodies of mammalian subjects when the binding protein is administered to mammalian subjects.
  • a concentration of the binding protein in the brain of a mammalian subject 96 hours after systemic administration to the mammalian subject is greater than 1 % of the concentration of the binding protein in the brain of a mammalian subject 24 hours after systemic administration to the mammalian subject.
  • the systemic administration is selected from the group consisting of intravenous administration, subcutaneous administration and intraperitoneal administration.
  • the binding protein is formulated for use with an applicator.
  • the applicator is a syringe, a dropper, a patch, a membrane, or a mesh.
  • the binding protein specifically binds to an antigen expressed on the brain vascular epithelium of a mammalian subject.
  • the mammal is selected from the group consisting of mice, rats, gerbils, hamsters, rabbits, apes, monkeys, humans, dogs, cats, camels, llamas, cattle and horses.
  • the antigen bound by the binding protein comprises a receptor expressed on brain vascular epithelium of a subject is selected from the group consisting of an insulin receptor, a transferrin receptor, a LRP, a melanocortin receptor, a nicotinic acetylcholine receptor, a VACM-1 receptor, vascular, IGFR, EPCR, EGFR, TNFR, leptin receptor, M6PR, a lipoprotein receptor, NCAM, LIFR, LfR, MRP1 , AchR, DTr, Glutathione transporter, SR-B1 , MYOF, TFRC, ECE1 ,LDLR, PVR, CDC50A, SCARF1 , MRC1 , HLA-DRA, RAMP2, VLDLR, STAB1 , TLR9, CXCL16, NTRK1 , CD74, DPP4, an endothelial growth factor receptor (EGFR) for example EGFR
  • EGFR endo
  • the binding protein further comprises a composition such that the composition is co-administered with the binding protein.
  • the composition comprises a pharmaceutically acceptable carrier or buffer.
  • the binding protein and composition are not-covalently linked and are mixed or contacted with one another.
  • the composition is covalently bound to the binding protein. In certain embodiments, the composition is covalently bound to the binding protein by a linker.
  • the composition is selected from the group consisting of budenoside, epidermal growth factor, a corticosteroid, cyclosporin, sulfasalazine, an aminosalicylate, 6-mercaptopurine, azathioprine, metronidazole, a lipoxygenase inhibitor, mesalamine, olsalazine, balsalazide, an antioxidant, a thromboxane inhibitor, an IL-1 receptor antagonist, an anti-IL-1 ⁇ mAbs, an anti-IL-6 or IL-6 receptor mAb, a growth factor, an elastase inhibitor, a pyridinyl-imidazole compound, an antibody or agonist of TNF, LT, IL-1 , IL-2, IL-6, IL-7, IL-8, IL-12, IL-13, IL-15, IL-16, IL-18, IL-23, EMAP-II, GM
  • prednisolone a phosphodiesterase inhibitor, an adenosine agonist, an antithrombotic agent, a complement inhibitor, an adrenergic agent, IRAK, NIK, IKK, p38, a MAP kinase inhibitor, an IL-1 ⁇ converting enzyme inhibitor, a TNFa-converting enzyme inhibitor, a T- cell signaling inhibitor, a metalloproteinase inhibitor, sulfasalazine, azathioprine, a 6- mercaptopurine, an angiotensin converting enzyme inhibitor, a soluble cytokine receptor, a soluble p55 TNF receptor, a soluble p75 TNF receptor, slL-1 Rl, slL-1 Rll, slL-6R, an antiinflammatory cytokine, IL-4, IL-10, IL- , IL-13, TGF , and combinations thereof.
  • the binding protein comprises a polypeptide chain, such that the polypeptide chain comprises VD1 -(X1 )n-VD2-C-(X2)n, such that
  • VD1 is a first heavy chain variable domain
  • VD2 is a second heavy chain variable domain
  • C is a heavy chain constant domain
  • X1 is a linker with the proviso that it is not CH1 ;
  • X2 is an Fc region
  • (X1 )n is (X1 )0 or (X1 )1 ;
  • (X2)n is (X2)0 or (X2)1 ;
  • binding protein specifically binds TfR or HIR
  • VD1 or VD2 comprises three CDRs wherein at least one CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 76, 77, 78, 82, 83, 1 15-117 and 156-158;
  • VD1 and VD2 independently comprise three CDRs wherein at least one CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 76, 77, 78, 82, 83, 1 15-117 and 156-158; or
  • VD1 comprises three CDRs wherein at least one CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 76, 77, 78, 82, 83, 1 15-1 17 and 156-158
  • VD2 comprises three CDRs wherein at least one CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 76, 77, 78, 82, 83, 1 15-1 17 and 156-158.
  • VD1 or VD2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 30, 32, 34, 36, 56, and 104; or
  • VD1 and VD2 independently comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 30, 32, 34, 36, 56, and 104.
  • the binding protein includes a polypeptide chain, such that the polypeptide chain comprises VD1 -(X1 )n-VD2-C-(X2)n, wherein
  • VD1 is a first light chain variable domain
  • VD2 is a second light chain variable domain
  • C is a light chain constant domain
  • X1 is a linker with the proviso that it is not CL;
  • X2 does not comprise an Fc region
  • (X1 )n is (X1 )0 or (X1 )1 ;
  • (X2)n is (X2)0 or (X2)1 ;
  • binding protein specifically binds TfR or HIR
  • VD1 or VD2 comprises three CDRs each, wherein at least one CDR comprises an amino acid sequences selected from the group consisting of SEQ ID NO: 79, 80, 81 , 84, 85, 86, 1 18, 119, 120, 159, 160, and 161 ;
  • VD1 and VD2 independently comprise three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 79, 80, 81 , 84, 85, 86, 1 18, 1 19, 120, 159, 160, and 161 ; or
  • VD1 comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 79, 80, 81 , 84, 85, 86, 1 18, 119, 120, 159, 160, and 161
  • VD2 comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 79, 80, 81 , 84, 85, 86, 1 18, 1 19, 120, 159, 160, and 161 .
  • VD1 or VD2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 31 , 33, 35, 37, 57, 105, 106, 107, and 108; or
  • VD1 and VD2 independently comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 31 , 33, 35, 37, 57, 105, 106, 1 07, and 108.
  • (X1 )n is (X1 )0.
  • the binding protein in certain embodiments comprises first and second polypeptide chains, wherein the first polypeptide chain comprises a first VD1 -(X1 )n-VD2-C- (X2)n, wherein
  • VD1 is a first heavy chain variable domain
  • VD2 is a second heavy chain variable domain
  • C is a heavy chain constant domain
  • X1 is a first linker
  • X2 is an Fc region
  • the second polypeptide chain comprises a second VD1 -(X1 )n-VD2- C-(X2)n, wherein
  • VD1 is a first light chain variable domain
  • VD2 is a second light chain variable domain ;
  • C is a light chain constant domain
  • X1 is a second linker
  • X2 does not comprise an Fc region
  • (X1 )n is independently (X1 )0 or (X1 )1 and (X2)n is independently (X2)0 or
  • first X1 linker is not CH1 and/or the second X1 linker is not CL;
  • binding protein specifically binds TfR or HI R
  • VD1 or VD2 heavy chain variable domain comprises three CDRs each, wherein at least one of the CDRs comprises an amino acid sequences selected from the group consisting of SEQ ID NO: 76, 77, 78, 82, 83, 1 15, 1 16, 1 17, 156, 157, and 158;
  • VD1 and VD2 heavy chain variable domains independently comprise three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 76, 77, 78, 82, 83, 1 15, 1 16, 1 17, 156, 157, and 158; or
  • VD1 heavy chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 76, 77, 78, 82, 83, 1 15, 1 16, 1 17, 156, 157, and 158
  • VD2 heavy chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ I D NO: 76, 77, 78, 82, 83, 1 15, 1 16, 1 17, 156, 157, and 158;
  • VD1 or VD2 light chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 79, 80, 81 , 84, 85, 86, 1 18, 119, 120, 159, 160, and 161 ;
  • VD1 and VD2 light chain variable domains independently comprise three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 79, 80, 81 , 84, 85, 86, 1 18, 1 19, 120, 159, 160, and 161 ; or
  • VD1 light chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 79, 80, 81 , 84, 85, 86, 1 18, 1 19, 120, 159, 160, and 161 ; and VD2 light chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 79, 80, 81 , 84, 85, 86, 1 18, 1 19, 120, 159, 160, and 161 .
  • VD1 or VD2 heavy chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 30, 32, 34, 36, 56, and 104; or
  • VD1 and VD2 heavy chain variable domains independently comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 30, 32, 34, 36, 56 and 104;
  • VD1 or VD2 light chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 31 , 33, 35, 37, 57, 105, 106, 107, and 108; or [078] (b) VD1 and VD2 light chain variable domains independently comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 31 , 33, 35, 37, 57, 105, 106, 107, and 108.
  • X1 is a peptide linker comprising an at least one amino acid sequence described herein.
  • the at one amino acid sequence is selected from a member of the group consisting of SEQ ID NOs 1 -29, 178 and 179.
  • the Fc region comprises a variant sequence Fc region.
  • the Fc region comprises an Fc region selected from the group consisting of lgG1 , lgG2, lgG3, lgG4, IgA, IgM, IgE, and IgD.
  • the Fc region comprises a humanized sequence or a human sequence.
  • the binding protein comprises two first polypeptide chains and two second polypeptide chains.
  • the VD1 of the first polypeptide chain and the VD1 of the second polypeptide chain are from a different first and second parent antibody, respectively, or antigen binding portion thereof.
  • the VD2 of the first polypeptide chain and the VD2 of the second polypeptide chain are from a different first and second parent antibody, respectively, or antigen binding portion thereof.
  • the first and the second parent antibodies bind different epitopes on the antigen.
  • the binding protein comprises a polypeptide chain, wherein the polypeptide chain comprises VD1 -(X1 )n-VD2-C-(X2)n, wherein
  • VD1 is a first heavy chain variable domain
  • VD2 is a second heavy chain variable domain
  • C is a heavy chain constant domain
  • X1 is a linker with the proviso that it is not CH1 ;
  • X2 is an Fc region
  • (X1 )n is (X1 )0 or (X1 )1 ;
  • (X2)n is (X2)0 or (X2)1 ;
  • binding protein specifically binds to a disease target selected from the group consisting of Abeta, BACE, Her-2, RGMA, TNFa and APP;
  • VD1 or VD2 comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 109, 1 10, 1 1 1 , 121 , 122, 123, 136, 137, 138, 139, 140, 141 , 142, 143, 147, 148, 149, 164, 165, 166, 172, 173, and 174;
  • VD1 and VD2 independently comprise three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 109, 1 10, 1 1 1 , 121 , 123, 136, 137, 138, 139, 140, 141 , 142, 143, 147, 148, 149, 164, 165, 166, 172, 173, and 174; or
  • VD1 comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 109, 1 10, 1 11 , 121 , 122, 123, 136, 137, 138, 139, 140, 141 , 142, 143, 147, 148, 149, 164, 165, 166, 172, 173, and 174; and VD2 comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 109, 1 10, 1 1 1 , 121 , 123, 136, 137, 138, 139, 140, 141 , 142, 143, 147, 148, 149, 164, 165, 166, 172, 173, and 174.
  • VD1 or VD2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 38, 58, 93, 94, 95, 96, 97, 98, 99, 101 , 167, and 169; or
  • VD1 and VD2 independently comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 38, 58, 93, 94, 95, 96, 97, 98, 99, 101 , 162, and 170.
  • the binding protein comprises a polypeptide chain, wherein the polypeptide chain comprises VD1 -(X1 )n-VD2-C-(X2)n, wherein
  • VD1 is a first light chain variable domain
  • VD2 is a second light chain variable domain
  • C is a light chain constant domain
  • X1 is a linker with the proviso that it is not CL;
  • X2 does not comprise an Fc region
  • (X1 )n is (X1 )0 or (X1 )1 ;
  • (X2)n is (X2)0 or (X2)1 ;
  • binding protein specifically binds to a disease target selected from the group consisting of Abeta, BACE, Her-2, RGMA, TNFa, and APP; and
  • VD1 or VD2 comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 1 12, 1 13, 1 14, 124, 125, 126, 127, 128, 129, 130, 131 , 132, 133, 134, 135, 150, 151 , 152, 167, 168, 169, 175, 176, and 177;
  • VD1 and VD2 independently comprise three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 1 12, 1 13, 1 14, 124, 125, 126, 127, 128, 129, 130, 131 , 132, 133, 134, 135, 150, 151 , 152, 167, 168, 169, 175, 176, and 177; or
  • VD1 comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 1 12, 1 13, 1 14, 124, 125, 126, 127, 128, 129, 130, 131 , 132, 133, 134, 135, 150, 151 , 152, 167, 168, 169, 175, 176, and 177
  • VD2 comprises three each comprising amino acid sequences selected CDRs from the group consisting of SEQ ID NO: 1 12, 1 13, 1 14, 124, 125, 126, 127, 128, 129, 130, 131 , 132, 133, 134, 135, 150, 151 , 152, 167, 168, 169, 175, 176, and 177.
  • VD1 or VD2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 39, 59, 87, 88, 89, 90, 91 , 92, 100, 102, 163, and 171 ; or
  • VD1 and VD2 independently comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 39, 59, 87, 88, 89, 90, 91 , 92, 100, 102, 163, and 171 .
  • the (X1 )n is (X1 )0.
  • the disclosure provides a binding protein comprising first and second polypeptide chains, wherein the first polypeptide chain comprises a first VD1 -(X1 )n-VD2-C- (X2)n, wherein
  • VD1 is a first heavy chain variable domain
  • VD2 is a second heavy chain variable domain
  • C is a heavy chain constant domain
  • X1 is a first linker
  • X2 is an Fc region
  • the second polypeptide chain comprises a second VD1 -(X1 )n-VD2- C-(X2)n, wherein
  • VD1 is a first light chain variable domain
  • VD2 is a second light chain variable domain
  • C is a light chain constant domain
  • X1 is a second linker
  • X2 does not comprise an Fc region
  • (X1 )n is independently (X1 )0 or (X1 )1 and (X2)n is independently (X2)0 or
  • first X1 linker is not CH1 and/or the second X1 linker is not CL;
  • binding protein specifically binds to a disease target selected from the group consisting of Abeta, BACE, Her-2, RGMA, TNFa and APP; and
  • VD1 or VD2 heavy chain variable domain comprises three CDRs each, wherein at least one CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 109, 1 10, 1 1 1 , 121 , 123, 136, 137, 138, 139, 140, 141 , 142, 143, 147, 148, 149, 164, 165, 166, 172, 173, and 174;
  • VD1 and VD2 heavy chain variable domains independently comprise three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 109, 1 10, 1 1 1 , 121 , 123, 136, 137, 138, 139, 140, 141 , 142, 143, 147, 148,
  • VD1 heavy chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 109, 1 10, 1 1 1 , 121 , 123, 136, 137, 138, 139, 140, 141 , 142, 143, 147, 148, 149, 164, 165, 166, 172, 173, and 174; and VD2 heavy chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 109, 1 10, 1 1 1 , 121 , 123, 136, 137, 138, 139, 140, 141 , 142, 143, 147, 148, 149, 164, 165, 166, 172, 173, and 174;
  • VD1 or VD2 light chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 1 12, 1 13, 1 14, 124, 125, 126, 127, 128, 129, 130, 131 , 132, 133, 134, 135, 150, 151 , and 152;
  • VD1 and VD2 light chain variable domains independently comprise three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 1 12, 1 13, 1 14, 124, 125, 126, 127, 128, 129, 130, 131 , 132, 133, 134, 135,
  • VD1 light chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 1 12, 1 13, 1 14, 124, 125, 126, 127, 128, 129, 130, 131 , 132, 133, 134, 135, 150, 151 , 152, 167, 168, 169, 175, 176, and 177
  • VD2 light chain variable domain comprises three each comprising amino acid sequences selected CDRs from the group consisting of SEQ ID NO: 1 12, 1 13, 1 14, 124, 125, 126, 127, 128, 129, 130, 131 , 132, 133, 134, 135, 150, 151 , 152, 167, 168, 169, 175, 176, and 177.
  • VD1 or VD2 heavy chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 38, 58, 93, 94, 95, 96, 97, 98, 99, 101 , 162, and 170; or
  • VD1 and VD2 heavy chain variable domains independently comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 38, 58, 93, 94, 95, 96, 97, 98, 99, 101 , 162, and 170;
  • VD1 or VD2 light chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 39, 59, 87, 88, 89, 90, 91 , 92, 100, 102, 163, and 171 ; or
  • VD1 and VD2 light chain variable domains independently comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 39, 59, 87, 88, 89, 90, 91 , 92, 100, 102, 163, and 171 .
  • the X1 is any one of the sequences described herein.
  • the X1 comprises any one of SEQ ID NOs 1 -29, 178 and 179.
  • the binding protein comprises two first polypeptide chains and two second polypeptide chains.
  • a first set of a first and a second polypeptide chain is as defined in claim 22 and a second set of a first and a second polypeptide chain is as defined in claim 36.
  • the Fc region is a variant sequence Fc region.
  • the Fc region is an Fc region from an lgG1 , lgG2, lgG3, lgG4, IgA, IgM, IgE, or IgD.
  • the Fc region is derived from a mammal, for example a human.
  • the VD1 of the first polypeptide chain and the VD1 of the second polypeptide chain are from a different first and second parent antibody, respectively, or antigen binding portion thereof.
  • the VD2 of the first polypeptide chain and the VD2 of the second polypeptide chain are from a different first and second parent antibody, respectively, or antigen binding portion thereof.
  • the first and the second parent antibodies bind different epitopes on the antigen.
  • the binding protein comprises a polypeptide chain, wherein the polypeptide chain comprises VD1 -(X1 )n-VD2-C-(X2)n, wherein
  • VD1 is a first heavy chain variable domain
  • VD2 is a second heavy chain variable domain
  • C is a heavy chain constant domain
  • X1 is a linker with the proviso that it is not CH1 ;
  • X2 is an Fc region
  • (X1 )n is (X1 )0 or (X1 )1 ;
  • (X2)n is (X2)0 or (X2)1 ;
  • binding protein specifically binds TfR or HIR and Abeta, BACE, Her-2, RGMA, TNFa, or APP;
  • VD1 or VD2 comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 76, 77, 78, 82, 83, 115-1 17, 156-158, 109, 1 10, 1 1 1 , 121 , 122, 123, 136, 137, 138, 139, 140, 141 , 142, 143, 147, 148, 149, 164, 165, 166, 172, 173, and 174;
  • VD1 and VD2 independently comprise three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 76, 77, 78, 82, 83, 1 15-117, 156-158, 109, 1 10, 1 1 1 , 121 , 122, 123, 136, 137, 138, 139, 140, 141 , 142, 143, 147, 148, 149,164, 165, 166, 172, 173, and 174;
  • VD1 comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 76, 77, 78, 82, 83, 1 15-1 17 and 156- 158
  • VD2 comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 109, 1 10, 1 1 1 , 121 , 122, 123, 136, 137, 138, 139, 140, 141 , 142, 143, 147, 148, 149, 164, 165, 166, 172, 173, and 174; or [0163]
  • VD2 comprises three CDRs each comprising amino acid sequences selected from SEQ ID NO: 76, 77, 78, 82, 83, 1 15-1 17 and 156-158
  • VD1 comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 109, 1 10, 1 1 1 , 121
  • VD1 or VD2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 30, 32, 34, 36, 56, 104, 38, 58, 93, 94, 95, 96, 97, 98, 99, 101 , 162, and 170; or
  • VD1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 30, 32, 34, 36, 56, or 104 and VD2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 38, 58, 93, 94, 95, 96, 97, 98, 99, 101 , 162, and 170.
  • the polypeptide chain comprises VD1 -(X1 )n-VD2-C-(X2)n, wherein
  • VD1 is a first light chain variable domain
  • VD2 is a second light chain variable domain
  • C is a light chain constant domain
  • X1 is a linker with the proviso that it is not CL;
  • X2 does not comprise an Fc region
  • (X1 )n is (X1 )0 or (X1 )1 ;
  • (X2)n is (X2)0 or (X2)1 ;
  • binding protein specifically binds TfR or HIR and Abeta, BACE, Her-2, or APP;
  • VD1 or VD2 comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 79, 80, 81 , 84, 85, 86, 1 18, 1 19, 120, 159, 160, 161 , 1 12, 1 13, 1 14, 124, 125, 126, 127, 128, 129, 130, 131 , 132, 133, 134, 135, 150, 151 , 152, 167, 168, 169, 175, 176, and 177;
  • VD1 and VD2 independently comprise three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 79, 80, 81 , 84, 85, 86, 1 18, 1 19, 120, 159, 160, 161 , 1 12, 1 13, 114, 124, 125, 126, 127, 128, 129, 130, 131 , 132, 133, 134, 135, 150, 151 , 152, 167, 168, 169, 175, 176, and 177;
  • VD1 comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 79, 80, 81 , 84, 85, 86, 1 18, 119, 120, 159, 160, and 161
  • VD2 comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 112, 1 13, 1 14, 124, 125, 126, 127, 128,
  • VD2 comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 79, 80, 81 , 84, 85, 86, 1 18, 119, 120, 159, 160, and 161 ; and VD1 comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 1 12, 1 13, 1 14, 124, 125, 126, 127, 128, 129, 130, 131 , 132, 133, 134, 135, 150, 151 , 152, 167, 168, 169, 175, 176, and 177.
  • VD1 or VD2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 31 , 33, 35, 37, 57, 105, 106, 107, 108, 39, 59, 87, 88, 89, 90, 91 , 92, 100, 102, 163, andl 71 ; or
  • VD1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 31 , 33, 35, 37, 57, 105, 106, 107, and 108 and VD2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 39, 59, 87, 88, 89, 90, 91 , 92, 100, 102, 163, and 171 .
  • (X1 )n is (X1 )0.
  • the binding protein comprising first and second polypeptide chains, wherein the first polypeptide chain comprises a first VD1 -(X1 )n-VD2-C- (X2)n, wherein
  • VD1 is a first heavy chain variable domain
  • VD2 is a second heavy chain variable domain
  • C is a heavy chain constant domain
  • X1 is a first linker
  • X2 is an Fc region
  • the second polypeptide chain comprises a second VD1 -(X1 )n-VD2- C-(X2)n, wherein
  • VD1 is a first light chain variable domain
  • VD2 is a second light chain variable domain
  • C is a light chain constant domain
  • X1 is a second linker
  • X2 does not comprise an Fc region
  • (X1 )n is independently (X1 )0 or (X1 )1 and (X2)n is independently (X2)0 or
  • first X1 linker is not CH1 and/or the second X1 linker is not CL;
  • binding protein specifically binds TfR or HI R and Abeta, BACE, Her-2, RGMA, TNFa, or APP;
  • VD1 or VD2 heavy chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 76, 77, 78, 82, 83, 1 15-1 17, 156-158, 109, 1 10, 1 1 1 , 121 , 122, 123, 136, 137, 138, 139, 140, 141 , 142, 143, 147, 148, 149, 1 64, 165, 166, 172, 173, and 174;
  • VD1 and VD2 heavy chain variable domains independently comprise three CDRs each comprising amino acid sequences selected from the group consisting of SEQ I D NO: 76, 77, 78, 82, 83, 1 15-1 1 7, 156-1 58, 1 09, 1 10, 1 1 1 , 121 , 122, 123, 136, 137, 138, 139, 140, 141 , 142, 143, 147, 148, 149, 164, 165, 166, 172, 173, and 1 74;
  • VD1 heavy chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 76, 77, 78, 82, 83, 1 15, 1 16, 1 17, 156, 157, 158, 164, 165, 166, 172, 173, and 1 74
  • VD2 heavy chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 109, 1 10, 1 1 1 , 121 , 123, 136, 137, 138, 139, 140, 141 , 142, 143, 147, 148, and 149; or
  • VD2 heavy chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 76, 77, 78, 82, 83, 1 15, 1 16, 1 17, 156, 157, 158, 164, 165, 166, 172, 173, and 1 74
  • VD1 heavy chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 109, 1 10, 1 1 1 , 121 , 122, 123, 136, 137, 138, 139, 140, 141 , 142, 143, 147, 148, andl 49; and wherein
  • VD1 or VD2 light chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 79, 80, 81 , 84, 85, 86, 1 18, 119, 120, 159, 160, 161 , 1 12, 1 13, 1 14, 124, 125, 126, 127, 128, 129, 130, 131 , 132, 133, 134, 135, 150, 151 , 152, 167, 168, 169, 175, 176, and 177;
  • VD1 and VD2 light chain variable domains independently comprise three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 79, 80, 81 , 84, 85, 86, 1 18, 1 19, 120, 159, 160, 161 , 1 12, 113, 114, 124, 125, 126, 127, 128, 129, 130, 131 , 132, 133, 134, 135, 150, 151 , 152, 167, 168, 169, 175, 176, and 177;
  • VD1 light chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 79, 80, 81 , 84, 85, 86, 1 18, 119, 120, 159, 160, 161 , 167, 168, 169, 175, 176, and 177; and VD2 light chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 1 12, 1 13, 1 14, 124, 125, 126, 127, 128, 129, 130, 131 , 132, 133, 134, 135, 150, 151 , and 152; or
  • VD2 light chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 79, 80, 81 , 84, 85, 86, 1 18, 119, 120, 159, 160, 161 , 167, 168, 169, 175, 176, and 177; and VD1 light chain variable domain comprises three CDRs each comprising amino acid sequences selected from the group consisting of SEQ ID NO: 1 12, 1 13, 1 14, 124, 125, 126, 127, 128, 129, 130, 131 , 132, 133, 134, 135, 150, 151 , and 152.
  • VD1 or VD2 heavy chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 30, 32, 34, 36, 56, 104, 38, 58, 93, 94, 95, 96, 97, 98, 99, 101 , -162, and 170; or
  • VD1 heavy chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 30, 32, 34, 36, 56, or 104 and VD2 heavy chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 38, 58, 93, 94, 95, 96, 97, 98, 99, 101 ,, 162, and 170;
  • VD1 or VD2 light chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 31 , 33, 35, 37, 57, 105, 106, 107, 108, 39, 59, 87, 88, 89, 90, 91 , 92, 100, 102, 163, and 171 ; or
  • VD1 light chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 31 , 33, 35, 37, 57, 105, 106, 107, or 108 and VD2 light chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 39, 59, 87, 88, 89, 90, 91 , 92, 100, or 102, 163, and 171.
  • X1 comprises any one of SEQ ID NOs 1 -29, 178 and 179.
  • the binding protein comprises two first polypeptide chains and two second polypeptide chains.
  • the Fc region is a variant sequence Fc region.
  • the Fc region is an Fc region from an lgG1 , lgG2, lgG3, lgG4, IgA, IgM, IgE, or IgD.
  • the VD1 of the first polypeptide chain and the VD1 of the second polypeptide chain are from a different first and second parent antibody, respectively, or antigen binding portion thereof.
  • the VD2 of the first polypeptide chain and the VD2 of the second polypeptide chain are from a different first and second parent antibody, respectively, or antigen binding portion thereof.
  • the first and the second parent antibodies bind different antigens.
  • the disclosure provides a monospecific binding protein comprising the heavy polypeptide chain of claim 17 and the light polypeptide chain of claim 19 or the heavy polypeptide claim of claim 31 and the light polypeptide chain of claim 33.
  • the disclosure provides a bispecific binding protein comprising the heavy polypeptide chain of claim 17 and the light polypeptide chain of claim 33; the heavy polypeptide claim of claim 31 and the light polypeptide chain of claim 19; the heavy polypeptide claim of claim 46 and the light polypeptide chain of claims 19, 33 or 48; or the heavy polypeptide claim of claims 17, 31 or 46 and the light polypeptide chain of claim 48.
  • the binding protein comprises Out1 -(X1 )m-ln1 -(X2)n, wherein In1 specifically binds to the antigen expressed on the brain vascular epithelium of the subject, wherein Out1 specifically binds to another molecule, wherein X1 is a linker, wherein X2 is an Fc region, wherein m is 0 or 1 and wherein n is 0 or 1.
  • the In1 specifically binds to the antigen expressed on the brain vascular epithelium of the subject with an EC50 of between about 5 nM and 0.01 nM.ln certain embodiments, the In1 specifically binds transferrin receptor. In certain embodiments, the In1 specifically binds the transferrin receptor with an EC50 less than 3 nM. In certain embodiments, the In1 comprises the amino sequence of SEQ ID NO:56. In certain embodiments, the X1 comprises the amino acid sequence of SEQ ID NO:179.
  • the Out1 binds another molecule selected from the group consisting of CGRP, TNFa, RGMA, Substance P, Bradykinin, Nav1 .7, LPA, P2X3, NGF, Abeta; BACE1 ; IL-1 ⁇ ; IGF1 ,or 2; IL-18; IL-6; RAGE; NGF; EGFR; cMet, Her -2 and CD-20.
  • the Out1 specifically binds to the antigen expressed on the brain vascular epithelium of the subject with an EC50 of between about 1 nM and 100 nM. In certain embodiments, the Out1 specifically binds transferrin receptor. In certain embodiments, the Out 1 specifically binds the transferrin receptor with an EC50 greater than 3 nM. In certain embodiments, the Out1 comprises the amino sequence of SEQ ID NO:36. In certain embodiments, the X1 comprises the amino acid sequence of SEQ ID NO:21 .
  • the In1 binds another molecule selected from the group consisting of CGRP, TNFa, RGMA, Substance P, Bradykinin, Nav1 .7, LPA, P2X3, NGF, Abeta; BACE1 ; IL-1 ⁇ ; IGF1 ,or 2; IL-18; IL-6; RAGE; NGF; EGFR; cMet, Her -2 and CD-20.
  • the first parent antibody or antigen binding portion thereof in certain embodiments binds the first antigen with a potency different from the potency with which the second parent antibody or antigen binding portion thereof, binds the second antigen.
  • the first parent antibody or antigen binding portion thereof in certain embodiments binds the first antigen with an affinity different from the affinity with which the second parent antibody or antigen binding portion thereof, binds the second antigen.
  • the binding protein in certain embodiments herein, the binding protein in certain
  • embodiments has an on rate constant (Kon) to the one or more targets of at least about 10 2 M “ ; at least about 10 3 M “ ; at least about 10 4 M “ ; at least about 10 5 M “ ; or at least about 10 6 M “ V, as measured by surface plasmon resonance.
  • Kon on rate constant
  • the binding protein in certain embodiments herein, the binding protein in certain
  • embodiments has an off rate constant (Koff) to the one or more targets of at most about 10 " 3 s ⁇ 1 ; at most about 10 "4 s “1 ; at most about 10 "5 s “1 ; or at most about 10 "6 s “1 , as measured by surface plasmon resonance.
  • Koff off rate constant
  • embodiemnts has a dissociation constant (K d ) to the one or more targets of at most about 10 ⁇ 7 M; at most about 10 ⁇ 8 M; at most about 10 ⁇ 9 M; at most about 10 ⁇ 10 M; at most about 10 "11 M; at most about 10 "12 M; or at most 10 "13 M.
  • K d dissociation constant
  • a further embodiment, of any of the heavy chain, light chain, two chain, or four chain embodiments includes at least one X1 linker comprising AKTTPKLEEGEFSEAR (SEQ ID NO: 1 ); AKTTPKLEEGEFSEARV (SEQ ID NO: 2); AKTTPKLGG (SEQ ID NO: 3); SAKTTPKLGG (SEQ ID NO: 4); SAKTTP (SEQ ID NO: 5); RADAAP (SEQ ID NO: 6);
  • RADAAPTVS SEQ ID NO: 7
  • RADAAAAGGPGS SEQ ID NO: 8
  • RADAAAA(G 4 S) 4 SEQ ID NO: 9
  • SAKTTPKLEEGEFSEARV SEQ ID NO: 10
  • ADAAP SEQ ID NO: 1 1
  • ADAAPTVSIFPP SEQ ID NO: 12
  • TVAAP SEQ ID NO: 13
  • TVAAPSVFIFPP SEQ ID NO: 14
  • QPKAAP SEQ ID NO: 15
  • QPKAAPSVTLFPP SEQ ID NO: 16
  • AKTTPP SEQ ID NO: 17
  • AKTTPPSVTPLAP SEQ ID NO: 18
  • AKTTAP SEQ ID NO: 19
  • AKTTAPSVYPLAP SEQ ID NO: 20
  • ASTKGP SEQ ID NO: 21
  • ASTKGPSVFPLAP SEQ ID NO: 22
  • GGGGSGGGGSGGGGS SEQ ID NO: 23
  • GENKVEYAPALMALS SEQ ID NO: 24
  • GPAKELTPLKEAKVS SEQ ID NO: 25
  • G H E AAAVMQVQ YP AS SEQ ID NO: 26
  • TVAAPSVFIFPPTVAAPSVFIFPP SEQ ID NO: 27
  • X2 is an Fc region. In another embodiment, X2 is a variant Fc region.
  • the linker comprises any of the sequences described herein, for example SEQ ID NOs: 1 -29, 178, or 179.
  • binding protein conjugate comprising a binding protein in any of the embodiments herein or in any of the claims.
  • the binding protein conjugate further comprises an agent, wherein the agent is an immunoadhension molecule, a diagnostic agent, an imaging agent, a therapeutic agent, or a cytotoxic agent.
  • the imaging agent is a radiolabel, an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a magnetic label, or biotin.
  • the binding protein is a crystallized binding protein.
  • a further embodiment provides a vector comprising the isolated nucleic acid disclosed herein wherein the vector is pcDNA; pTT (Durocher et al. (2002) Nucleic Acids Res. 30(2); pTT3 (pTT with additional multiple cloning site; pEFBOS
  • the vector is a vector disclosed in US Patent Publication No. 20090239259, incorporated by reference in its entirety.
  • the disclosure provides an isolated nucleic acid encoding the binding protein amino acid sequence in any of the embodiments described herein or any of the claims.
  • the disclosure provides a vector comprising an isolated nucleic acid described herein.
  • the vector comprises the isolated nucleic acid described in claim 82.
  • the vector is pcDNA, pTT, pTT3, pEFBOS, pBV, pJV, pcDNA3.1 TOPO, pEF6 TOPO, pHybE, pBOS or pBJ.
  • a host cell is transformed with the vector disclosed herein.
  • the host cell is a prokaryotic cell, for example, E.coli.
  • the host cell is a eukaryotic cell, for example, a protist cell, an animal cell, a plant cell, or a fungal cell.
  • the host cell is a mammalian cell including, but not limited to, CHO, COS, NS0, SP2, PER.C6, or a fungal cell, such as Saccharomyces cerevisiae, or an insect cell, such as Sf9.
  • two or more binding proteins e.g., with different specificities, are produced in a single recombinant host cell.
  • OligoclonicsTM OligoclonicsTM (Merus B.V., The Netherlands) US Patent Nos. 7,262,028 and 7,429,486.
  • the disclosure provides also a method of producing a binding protein disclosed herein comprising culturing any one of the host cells disclosed herein in a culture medium under conditions sufficient to produce the binding protein is provided.
  • 50%-75% of the binding protein produced by this method is a dual specific tetravalent binding protein.
  • 75%-90% of the binding protein produced by this method is a dual specific tetravalent binding protein.
  • 90%-95% of the binding protein produced is a dual specific tetravalent binding protein.
  • the disclosure provides a method for treating a mammal comprising administering to the mammal an effective amount of the binding protein.
  • the disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising the binding protein described herein including for example the binding protein of any of the claims, and a pharmaceutically acceptable carrier.
  • the composition further comprises at least one additional therapeutic agent.
  • the additional therapeutic agent is an imaging agent, a cytotoxic agent, an angiogenesis inhibitor, a kinase inhibitor, a co- stimulation molecule blocker, an adhesion molecule blocker, an anti-cytokine antibody or functional fragment thereof, methotrexate, cyclosporin, rapamycin, FK506, a detectable label or reporter, a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a nonsteroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid, an erythropoietin, an immunization, an immunoglobulin, an imaging agent, a cytotoxic agent, an angiogenesis inhibitor, a kinase inhibitor
  • immunosuppressive a growth hormone, a hormone replacement drug, a
  • radiopharmaceutical an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.
  • the additional therapeutic agent is selected from the group consisting of budenoside, epidermal growth factor, a corticosteroid, cyclosporin, sulfasalazine, an aminosalicylate, 6-mercaptopurine, azathioprine, metronidazole, a lipoxygenase inhibitor, mesalamine, olsalazine, balsalazide, an antioxidant, a thromboxane inhibitor, an IL-1 receptor antagonist, an anti-IL-1 ⁇ mAbs, an anti-IL-6 or IL-6 receptor mAb, a growth factor, an elastase inhibitor, a pyridinyl-imidazole compound, an antibody or agonist of TNF, LT, IL-1 , IL-2, IL-6, IL-7, IL-8, IL-12, IL-13, IL-15, IL-16, IL-18, IL-23, EMAP-II,
  • prednisolone a phosphodiesterase inhibitor, an adenosine agonist, an antithrombotic agent, a complement inhibitor, an adrenergic agent, IRAK, NIK, IKK, p38, a MAP kinase inhibitor, an IL-1 ⁇ converting enzyme inhibitor, a TNFa-converting enzyme inhibitor, a T- cell signaling inhibitor, a metalloproteinase inhibitor, sulfasalazine, azathioprine, a 6- mercaptopurine, an angiotensin converting enzyme inhibitor, a soluble cytokine receptor, a soluble p55 TNF receptor, a soluble p75 TNF receptor, slL-1 Rl, slL-1 Rll, slL-6R, an antiinflammatory cytokine, IL-4, IL-10, IL- , IL-13, TGF and combinations thereof.
  • the disclosure provides the binding protein in any of the embodiments herein for use in treating a subject for a disease or a disorder by administering to the subject the binding protein such that treatment is achieved.
  • the disorder is a brain disorder.
  • the brain disorder is an autoimmune or inflammatory disease of the brain, an infectious disorder of the brain, a neurological disorder, a neurodegenerative disorder, a brain cancer, or a brain metastasis.
  • the disorder is selected from the group consisting of: Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke, mental disorders, depression, schizophrenia, acute pain, and chronic pain.
  • administering to the subject is parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.
  • the disclosure provides a method for generating a binding protein capable of binding two antigens, the method comprising the steps of:
  • the Fc region is a variant sequence Fc region.
  • the Fc region is an Fc region from an lgG1 , lgG2, lgG3, lgG4, IgA, IgM, IgE, or IgD.
  • the first parent antibody or antigen binding portion thereof if present, binds the first antigen with a different affinity and/or potency than the affinity and/or potency with which the second parent antibody or antigen binding portion thereof, if present, binds the second antigen.
  • the disclosure also provides a method of determining the presence of at least one antigen or fragment thereof in a test sample by an immunoassay.
  • the immunoassay comprises contacting the test sample with at least one binding protein and at least one detectable label, wherein the at least one binding protein comprises the binding protein of any of the preceding claims.
  • the method further comprises: [0258] (i) contacting the test sample with the at least one binding protein, wherein the binding protein binds to an epitope on the antigen or fragment thereof so as to form a first complex;
  • the method further comprising:
  • test sample is from a patient and the method further comprises diagnosing, prognosticating, or assessing the efficiency of
  • the method further comprises assessing the efficacy of therapeutic/prophylactic treatment of the patient, the method optionally further comprises modifying the therapeutic/prophylactic treatment of the patient as needed to improve efficacy.
  • the method is adapted for use in an automated system or a semi-automated system. In certain embodiments, wherein the method determines the presence of more than one antigen in the sample.
  • the disclosure provides a method of determining the amount or concentration of an antigen or fragment thereof in a test sample by an immunoassay
  • the immunoassay (a) employs at least one agent and at least one detectable label and (b) comprises comparing a signal generated by the detectable label with a control or a calibrator comprising the antigen or fragment thereof,wherein the calibrator is optionally part of a series of calibrators in which each calibrator differs from the other calibrators in the series by the concentration of the antigen or fragment thereof, wherein the at least one agent comprises the binding protein of any of the preceding claims.
  • the method further comprising:
  • the method further comprising:
  • test sample is from a patient and the method further comprises diagnosing, prognosticating, or assessing the efficiency of
  • the method further comprises assessing the efficacy of therapeutic/prophylactic treatment of the patient, the method optionally further comprises modifying the therapeutic/prophylactic treatment of the patient as needed to improve efficacy.
  • the method is adapted for use in an automated system or a semi-automated system. In certain embodiments, the method determines the amount or concentration of more than one antigen in the sample.
  • the disclosure also provides a kit for assaying a test sample for the presence, amount, or concentration of an antigen or fragment thereof, the kit comprising
  • the disclosure provides a humanized antibody that specifically binds TfR comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 30- 37, 56 and 57.
  • the disclosure provides a humanized antibody that specifically binds HIR comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 104-108.
  • polypeptide comprising an amino acid sequence of SEQ ID NO:103, wherein the polypeptide can be bound to the binding protein or unbound to the binding protein.
  • Figure 1 is a schematic representation of Dual Variable Domain (DVD) binding protein constructs.
  • Figure 2 is a micrograph of brain tissue showing elevation of TfR mAb in brain extracts (MSD-ECL) localized to parenchyma and neuronal cell bodies (IHC) after therapeutic dosing.
  • Figure 3 is a micrograph of brain tissue showing elevated DVD-lgTM levels were localized to Purkinje cells in cerebellum and cranial nerve cell bodies by IHC.
  • Figure 4 is a flow chart representation of methods and systems used for generation and in vitro/in vivo screening of receptor-mediated transcytosis domain DVD- Igs.
  • Figure 5 is a drawing/representation of an exemplary DVD Ig.
  • the DVD immunoglobulin includes at least one variable domain that specifically binds a BBB antigen (anti-BBB antigen), and a different at least one variable domain that specifically binds target X.
  • the DVD-lg in various embodiments is a TNF/TfR, RGMA/TfR, Abeta/TfR, and Her2/TfR.
  • Figure 6 is a drawing/representation of an in vivo tissue distribution protocol used for analyzing characteristics of antibody or a DVD-lgTM.
  • Figure 7 is a micrograph of stained brain tissue from subjects administered either: 40 mpk of control human IgG at 24 hours; 20mpK of a 8C1 1 -hFc DVD at 48 hours; 30 mpK of a non-specific DVD control at 48 hours; 20 mpk of TNF-GS-AB221 DVD at 24 hours; or 20 mpk of TfR(AB405)-SL-TNF DVD at 24 hours.
  • Figure 8 is a bar graph showing the percent maximum possible effect (%MPE; ordinate) at day 1 and day 5 for BALB-C murine subjects 15 days after Bennett surgery and after intrathecally injection (abscissa) with: control IgG (48 ⁇ g/10 ⁇ dose per injection); 8C11 -GS-AB221 DVD-lg (anti-TNFa/ anti-TfR; 55 ⁇ /10 ⁇ dose per injection); or morphine (10 ⁇ g/10 ⁇ dose per injection). The injections were performed daily for five days after the Bennett surgery. Mechanical allodynia was assessed in the Bennett model 120 minutes post-injection administrations at day 1 and day 5.
  • %MPE percent maximum possible effect
  • Figure 9 is a bar graph showing the percent efficacy (ordinate) at day 1 and day 5 for murine subjects 15 days after intravenous injection (abscissa) with control IgG (48 ⁇ /10 ⁇ / dose per injection); 8C1 1 -GS-AB221 DVD (anti-TNFa/ anti-TfR; 55 ⁇ /10 ⁇ / dose per injection); or an acute post-operation dose of gabapentin (10 ⁇ /10 ⁇ / dose per injection). The injections were performed daily for five days after the Bennett surgery. Mechanical allodynia was assessed in the above Bennett model 120 minutes post-injection administration at day 1 and at day 5.
  • Figure 10 is a micrograph of stained brain tissue from subjects administered either: 40 mpk of RGMA (AE12-1 )-hFc at 24 hours; 30 mpk human IgG control; 20 mpk of RGMA (AE12-1 )-GS-AB403 DVD-lg, or 30 mpk of RGMA (AE12-1 )-GS-AB403 DVD-lg.
  • the invention provides multivalent and/or multispecific binding proteins capable of binding receptors expressed on the brain vascular epithelium.
  • Structures at the blood brain barrier (“BBB") enabling such transport include but are not limited to the insulin receptor, transferrin receptor, LRP, melanocortin receptor, nicotinic acetylcholine receptor, VACM-1 receptor, vascular endothelial growth factor receptors 1 , 2 and 3, glucocorticoid receptor, ionotropic glutamate receptor, M3 receptor, aryl hydrocarbon receptor, GLUT-1 , inositol-1 ,4,5-trisphosphate (IP3) receptor, N-methyl-D- aspartate receptor, S1 P1 , P2Y receptor and RAGE.
  • BBB blood brain barrier
  • multivalent and/or multispecific binding proteins bind to the binding receptors expressed on the brain vascular epithelium as well as a therapeutic target.
  • therapeutic targets include for example CGRP, TNFa, RGMA, Substance P, Bradykinin, Nav1.7, LPA, P2X3, NGF, Abeta; BACE1 ; IL-1 ⁇ ; IGF1 ,or 2; IL- 18; IL-6; RAGE; NGF; EGFR; cMet; Her-2; and CD-20.
  • the binding protein or peptide in various embodiments comprises an amino acid sequence that specifically binds to an epitope, antigen, receptor or target, such that the binding protein or peptide is effective for transport to or across the BBB.
  • the amino acid sequence includes at least about three amino acids, at least about five amino acids, at least about seven amino acids, at least about ten amino acids, at least about 15 amino acids, or at least 20 amino acids that binds to an epitope, antigen, receptor or target, such that the binding protein or peptide is effective for transport to or across the BBB.
  • the epitope, antigen, receptor or target includes for example an insulin receptor, a transferrin receptor, a low density lipoprotein receptor-related protein (LRP) for example LRP-1 and LRP-8, melanocortin receptor, nicotinic acetylcholine receptor, VACM-1 receptor, vascular endothelial growth factor receptors 1 , 2 and 3, glucocorticoid receptor, ionotropic glutamate receptor, M3 receptor, aryl hydrocarbon receptor, GLUT-1 , inositol-1 ,4,5-trisphosphate (IP3) receptor, N-methyl-D-aspartate receptor, S1 P1 , P2Y receptor, and RAGE.
  • LRP low density lipoprotein receptor-related protein
  • melanocortin receptor melanocortin receptor
  • nicotinic acetylcholine receptor VACM-1 receptor
  • the binding protein or peptide is also capable of modulating a biological function of one or more targets.
  • the binding protein or peptide comprises an amino acid sequence that specifically binds to an epitope, antigen, receptor or target, such that a biological function is modulated.
  • the epitope, antigen, receptor or target can be selected from CGRP, TNFa, RGMA, Substance P, Bradykinin, Nav1.7, LPA, P2X3, NGF, Abeta; BACE1 ; IL-1 ⁇ ; IGF1 ,or 2; IL-18; IL-6; RAGE; NGF; EGFR; cMet; Her-2; and CD-20.
  • the binding protein or peptide comprises; a Fv; a Fab; a Fab'; a F(ab') 2 , or a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region.
  • the binding protein includes at least one heavy variable region (VH) and at least one light variable region (VL).
  • the binding protein or peptide includes a VH and CH1 domains; VL and VH domains; or an isolated complementarity determining region (CDR).
  • the binding protein or peptide comprises at least one VH, at least one VL, or at least one hypervariable (hv) site.
  • the binding or peptide includes a constant region.
  • the constant region is from a mammal, e.g., a human and a mouse.
  • the binding protein is monospecific for an epitope or antigen.
  • the binding protein or peptide is effective for transport to or across the BBB.
  • two or more distinct binding regions are combined to construct a chimeric binding protein or peptide.
  • the chimeric protein includes at least two non-identical binding regions.
  • the binding protein comprises a DVD-lgTM as described herein.
  • the binding protein or peptide includes at least one binding region that specifically binds an epitope, an antigen, a receptor or a target.
  • the binding protein comprises a single chain.
  • the binding protein comprises a plurality of chains, i.e., at least two polypeptide chains.
  • the binding protein or peptide comprises a plurality of binding regions which are ordered or orientated such that each binds to the same or different portion of an epitope, an antigen, a receptor or a target.
  • the at least one binding region is positioned proximally and/or distally to another binding region, such that each is present on the same or different variable region/domain.
  • the binding regions are positioned parallel to one another, for example on a VH and a VL.
  • the binding regions are positioned opposite or facing one another, for example a first binding region is within a first VH or first VL, and a second binding region is within a second VH or a second VL.
  • the multiple binding regions are each bound to the same separate/third portion (e.g., a constant domain or linker), such that each binding region may interact or alternatively does not interact with one another.
  • the binding protein is a molecule with the ability to monospecifically bind a receptor, antigen or target and cross the BBB.
  • the binding protein is formulated, compounded or administered in a form (e.g., nanoparticle; liposome, mixture, or solution) and is delivered along with an agent to the brain.
  • the binding protein is administered in a composition including the agent (e.g., a peptide or protein).
  • the binding protein in bound or attached to the agent.
  • the binding protein and agent are administered within the composition.
  • the agent or binding protein is administered before or after one another over a period of seconds, minutes, hours or days of one another.
  • the binding protein is bi-specific and binds two different antigens (or epitopes).
  • the binding protein specifically binds a receptor, antigen or target for crossing the BBB, and also specifically binds another target in the brain.
  • the binding protein comprises at least one VH and at least one VL.
  • the binding protein comprises a DVD-lgTM as described herein.
  • the binding protein includes at least two VH domains. In some embodiments, one VH domain specifically binds a receptor, antigen or target for crossing the BBB and another VH domain specifically binds another target in the brain. In other embodiments, the binding protein includes at least two VL domains. In some embodiments, one VL domain specifically binds a receptor, antigen or target for crossing the BBB and another VL domain specifically binds another target in the brain. In other embodiments, the binding protein includes at least two VH and at least two VL domains.
  • one VL domain specifically binds a receptor, antigen or target for crossing the BBB and another VH domain specifically binds another target in the brain while one VH domain specifically binds a receptor, antigen or target for crossing the BBB and another VH domain specifically binds another target in the brain.
  • the binding protein is made up of two polypeptides or arms.
  • Each of the arms can have one or more VH and VL domains.
  • each arm has two VH and two VL domains.
  • the arms have only two VH or two VL domains.
  • the binding protein comprises two arms/regions and each arm binds the same target or binds at least two different targets. For example, one arm binds the receptor, antigen or target for crossing the BBB, and the other arm upon crossing the BBB binds a different target on or in the brain (brain target).
  • a VH or VL on one arm binds the receptor for crossing the BBB, and a VH or VL on the other arm binds to the target.
  • the binding protein has two identical antigen binding arms, in which each arm contains a VH/VL that binds the receptor for crossing the BBB, and a VH/VL that binds to a target found inside of the brain upon crossing the BBB.
  • each arm has identical specificity and identical CDR sequences.
  • the binding protein is a DVD-lg that contains a VH1 or VH2 that binds to the BBB receptor or binds to the target on or in the brain.
  • the VH1 or VL1 binds to the BBB receptor, and the VH2 or VL2 binds to the target on or in the brain.
  • the VH2 or VL2 binds to the BBB receptor, and the VH1 or VL2 binds to the target on or in the brain.
  • the binding protein comprises a DVD-lgTM as described herein that binds at least two different targets.
  • the binding protein is a DVD-lg contains a VH1 that binds to the BBB receptor, and a VH2 that binds to the target on or in the brain.
  • the binding protein is a DVD-lg contains a VH2 that binds to the BBB receptor, and a VH1 that binds to the target on or in the brain.
  • the VL1 binds to the BBB receptor, and the VL2 binds to the target on or in the brain.
  • the VL2 binds to the BBB receptor, and the VL1 binds to the target on or in the brain.
  • the binding protein or peptide comprises a variable binding region.
  • the variable binding region comprises a VH or VL.
  • the VL is located proximally or distally to the VL.
  • the VH is adjacent, bound or connected to the VL.
  • the VH is directly contacted to the VL, or the VH is connected to the VL by a linker.
  • the VH is parallel or adjacent to the VL.
  • the VH is separated from the VL by a covalent bond that maintains the VH and the VL in a confirmation or orientation.
  • the binding protein or peptide comprises a polypeptide chain having a structure VD1 -(X1 )n-VD2-C-(X2)n, such that VD1 is a first variable domain, VD2 is a second variable domain, C is a constant domain, X1 represents an amino acid or polypeptide, X2 represents an Fc region and n is 0 or 1 .
  • the VD1 and VD2 in the binding protein are heavy chain variable domains.
  • VD1 and VD2 are capable of binding the same antigen.
  • VD1 and VD2 are capable of binding the same antigen.
  • VD1 and VD2 are capable of binding different antigens.
  • C is a heavy chain constant domain.
  • X1 is a linker with the proviso that X1 is not CH1 .
  • the binding protein or peptide disclosed herein comprises a polypeptide chain that binds the epitope, receptor or antigen, such that the polypeptide chain comprises VD1 -(X1 )n-VD2-C-(X2)n, and VD1 is a first heavy chain variable domain, VD2 is a second heavy chain variable domain, C is a heavy chain constant domain, X1 is a linker, and X2 is an Fc region.
  • X1 is a linker with the proviso that it is not CH1 .
  • the binding protein or peptide is attached or linked to an agent (e.g., a therapeutic agent or diagnostic agent).
  • an agent e.g., a therapeutic agent or diagnostic agent.
  • the binding protein or peptide includes a linker that separates the binding regions and/or that separates the binding protein or peptide from the agent.
  • the linker in a related embodiment separates the binding regions and/or subunits of the binding protein or peptide.
  • the binding protein or peptide includes a linker that covalently joins at least one binding region (e.g., a VH or a VL) to at least one other amino acid residue or domain.
  • the linker includes at least one selected from the group of a peptide, a protein, a sugar, or a nucleic acid.
  • the linker includes an amino acid sequence described herein or a portion thereof or multiples thereof.
  • the linker in various embodiments stabilizes the binding protein or peptide and does not prevent the respective binding of a binding region or the peptide to the epitope, antigen, receptor or target, such that the protein or peptide is effective for transport to or across the BBB.
  • the binding protein comprises a linker that reduces steric hindrance.
  • the binding protein peptide is recombinantly produced.
  • the recombinant binding protein is encoded by a nucleotide sequence or the binding protein includes an amino acid sequence that is substantially identical or homologous to the sequences described herein, for example a sequence shown in any of the Examples and Tables herein.
  • recombinant binding protein or peptide is engineered and constructed using any of the sequences described herein.
  • the binding protein or peptide is administered to a subject using a vector carrying a nucleotide sequence that encodes the binding protein or peptide.
  • the binding protein or peptide (with or without an agent) is delivered for example using a liposome, a lipid/polycation (LPD), a peptide, a nanoparticle, a gold particle, and a polymer.
  • a liposome a lipid/polycation (LPD)
  • LPD lipid/polycation
  • a peptide a nanoparticle, a gold particle, and a polymer.
  • the binding protein or peptide includes an amino acid sequence having a conservative sequence modification from the sequences shown herein, e.g., SEQ ID NOs: 1 -185 or sequences in Tables 1 -18.
  • conservative sequence modifications refers to amino acid modifications that do not significantly affect or alter the characteristics (e.g., binding, stability, and orientation) of the binding protein, e.g., amino acid sequences of binding protein that present a side chain at the same relative position to allow for function in a manner similar to an unmodified binding protein.
  • a conservative modification includes for example a substitution, addition, or deletion in the amino acid sequence of the binding protein or peptide.
  • Modification of the amino acid sequence of recombinant multimeric binding protein is achieved using any known technique in the art e.g., site-directed mutagenesis or PCR based mutagenesis. Such techniques are described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Plainview, N.Y., 1989 and Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, N.Y., 1989. Conservative amino acid substitutions are modifications in which the amino acid residue is replaced with an amino acid residue having a similar side chain such as replacing a small amino acid with a different small amino acid, a hydrophilic amino acid with a different hydrophilic amino acid, etc.
  • the multivalent binding protein has a molecular weight of greater than 150 kilodaltons (kD). In other embodiments, the binding protein has a molecular weight between 150 kD and 1000 kD. In other embodiments, the binding protein has a molecular weight between 150 kD and 500 kD, 150kD and 350 kD, 150 kD and 250 kD and 150 kD and 750 kD.
  • the binding protein has a molecular weight of greater than 150, 200, 250, 300, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1 100, 1 150, 1200, 1250, 1300, 1350, 1400, 1450 and 1500 kD.
  • the DVD binding proteins can bind to an antigen (e.g., a target and a receptor) expressed on the brain vascular epithelium and have another unoccupied binding site.
  • This unoccupied binding site can be specific for a composition (e.g., an endogenous or exogenous therapeutic protein) to be co-transported across the BBB.
  • binding proteins "pre-loaded” in this fashion can be delivered to a desired target site in the brain to exert its desired therapeutic activity.
  • the binding site can remain unoccupied following transport and BBB uptake via binding to the receptor expressed on the brain vascular epithelium so that it is capable of binding a desired target molecule on the brain side of the BBB.
  • the binding affinity of a binding protein to an antigen e.g., a receptor
  • the binding proteins specifically bind to the receptor expressed on the brain vascular epithelium, but they can bind at the lower end of the binding affinity range for specific binding.
  • the binding protein will bind to a receptor expressed on the brain vascular epithelium with dissociation constant of between 1 x10 ⁇ 6 M and 1x10 ⁇ 7 .
  • the dissociation constant is between 1 x10 ⁇ 6 M and 1 x10 ⁇ 8 .
  • lower affinity is achieved through the humanization of antibodies from non-human mammals.
  • the binding protein will bind the receptor expressed on the brain vascular epithelium with different affinities.
  • the binding protein is a DVD binding protein.
  • the DVD binding protein comprises two arms. Each arm includes a heavy and a light chain. Each heavy and light chain includes a variable domain.
  • DVD binding proteins can include 8 variable domains or 4 binding sites comprising 4 VH/VL pairs. Each of these domains can specifically bind a given antigen with a different dissociation constant. In some embodiments, the domain will bind to an antigen with dissociation constant of between 1 x10 "6 M and 1 x10 "7 .
  • the dissociation constant is between 1 x10 "6 M and 1 x10 "8 .
  • the antigen is a receptor expressed on the brain vascular epithelium, a composition to be co-transported across the BBB or a target on the brain side of the BBB.
  • the binding protein that specifically binds to a receptor expressed on the brain vascular epithelium can have a 2 or more fold increase in uptake of a composition across the blood brain barrier (BBB) compared to a control non-specific binding protein.
  • BBB blood brain barrier
  • the binding protein that specifically binds to a receptor expressed on the brain vascular epithelium can have a 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 fold or more fold increase in uptake of a composition across the BBB compared to a control non-specific binding protein.
  • a composition is co-administered with the binding protein that specifically binds to a receptor expressed on the brain vascular epithelium.
  • This composition can be directly bound to the binding protein or it can be coadministered in an unconjugated form.
  • the composition is bound through a linker.
  • the linker can be a polypeptide linker.
  • the linker can also be a non-polypeptide linker. Many such linkers are known in the art.
  • the composition co-administered with the binding protein can be selected from one or more of the following budenoside, epidermal growth factor, a corticosteroid, cyclosporin, sulfasalazine, an aminosalicylate, 6-mercaptopurine, azathioprine, metronidazole, a lipoxygenase inhibitor, mesalamine, olsalazine, balsalazide, an antioxidant, a thromboxane inhibitor, an IL-1 receptor antagonist, an anti-IL-1 ⁇ mAbs, an anti-IL-6 or IL-6 receptor mAb, a growth factor, an elastase inhibitor, a pyridinyl- imidazole compound, an antibody or agonist of TNF, LT, IL-1 , IL-2, IL-6, IL-7, IL-8, IL-12, IL-13, IL-15, IL-16, IL-18,
  • antibody refers to an immunoglobulin (Ig) molecule, which is generally comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains, or a functional fragment, mutant, variant, or derivative thereof, that retains the epitope binding features of an Ig molecule.
  • Ig immunoglobulin
  • each heavy chain is comprised of a heavy chain variable region (VH) and a heavy chain constant region (CH).
  • the CH is comprised of three domains, CH1 , CH2 and CH3.
  • Each light chain is comprised of a light chain variable region (VL) and a light chain constant region (CL).
  • the CL is comprised of a single CL domain.
  • the VH and VL can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs).
  • CDRs complementarity determining regions
  • FRs framework regions
  • each VH and VL is composed of three CDRs and four FRs, arranged from amino- terminus to carboxy-terminus in the following order: FR1 , CDR1 , FR2, CDR2, FR3, CDR3, and FR4.
  • Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., lgG1 , lgG2, lgG3, lgG4, lgA1 and lgA2), or subclass.
  • bispecific antibody refers to an antibody that binds one antigen (or epitope) on one of its two binding arms (one pair of HC/LC), and binds a different antigen (or epitope) on its second binding arm (a different pair of HC/LC).
  • a bispecific antibody has two distinct antigen binding arms (in both specificity and CDR sequences), and is monovalent for each antigen to which it binds.
  • Bispecific antibodies include those generated by quadroma technology (Milstein and Cuello (1983) Nature 305(5934): 537-40), by chemical conjugation of two different monoclonal antibodies (Staerz et al.
  • An "affinity matured” antibody is an antibody with one or more alterations in one or more CDRs thereof which result an improvement in the affinity of the antibody for antigen, compared to a parent antibody which does not possess those alteration (s).
  • Exemplary affinity matured antibodies will have nanomolar or even picomolar affinities for the target antigen.
  • Affinity matured antibodies are produced by procedures known in the art. Marks et al. (1992) BioTechnology 10:779-783 describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of CDR and/or framework residues is described by Barbas et al. (1994) Proc. Nat. Acad. Sci. USA 91 :3809-3813; Schier et al. (1995) Gene 169:147-155; Yelton et al. (1995) J. Immunol. 155:1994-2004; Jackson et al. (1995) J.
  • CDR-grafted antibody refers to an antibody that comprises heavy and light chain variable region sequences in which the sequences of one or more of the CDR regions of VH and/or VL are replaced with CDR sequences of another antibody.
  • the two antibodies can be from different species, such as antibodies having murine heavy and light chain variable regions in which one or more of the murine CDRs has been replaced with human CDR sequences.
  • humanized antibody refers to an antibody from a non-human species that has been altered to be more "human-like", i.e., more similar to human germline sequences.
  • One type of humanized antibody is a CDR-grafted antibody, in which non- human CDR sequences are introduced into human VH and VL sequences to replace the corresponding human CDR sequences.
  • a “humanized antibody” is also an antibody or a variant, derivative, analog or fragment thereof that comprises framework region (FR) sequences having substantially (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% identity to) the amino acid sequence of a human antibody and at least one CDR having substantially the amino acid sequence of a non-human antibody.
  • FR framework region
  • a humanized antibody may comprise substantially all of at least one, and typically two, variable domains (Fab, Fab', F(ab') 2, FabC, Fv) in which the sequence of all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin (i.e., donor antibody) and the sequence of all or substantially all of the FR regions are those of a human immunoglobulin.
  • the humanized antibody also may include the CH1 , hinge, CH2, CH3, and CH4 regions of the heavy chain.
  • a humanized antibody also comprises at least a portion of a human immunoglobulin Fc region.
  • a humanized antibody only contains a humanized light chain.
  • a humanized antibody only contains a humanized heavy chain. In some embodiments, a humanized antibody only contains a humanized variable domain of a light chain and/or humanized variable domain of a heavy chain. In some embodiments, a humanized antibody contains a light chain as well as at least the variable domain of a heavy chain. In some embodiments, a humanized antibody contains a heavy chain as well as at least the variable domain of a light chain.
  • variable variable domain binding protein and “dual variable domain immunoglobulin” refer to a binding protein that has two variable domains in each polypeptide chain of its binding arm(s) (e.g., a pair of HC/LC) (see PCT Publication No. WO 02/02773), each of which is able to bind to an antigen.
  • each variable domain binds different antigens or epitopes.
  • each variable domain binds the same antigen or epitope.
  • a dual variable domain binding protein has two identical antigen binding arms, with identical specificity and identical CDR sequences, and is bivalent for each antigen to which it binds.
  • the DVD binding proteins may be monospecific, i.e., capable of binding one antigen or multispecific, i.e., capable of binding two or more antigens.
  • DVD binding proteins comprising two heavy chain DVD polypeptides and two light chain DVD polypeptides are referred to as a DVD-lgTM.
  • the DVD binding protein includes at least one region that binds a BBB antigen.
  • the DVD-lg further includes at least one other region that binds to or a receptor, antigen, target, cell or tissue of the brain.
  • each half of a four chain DVD binding protein comprises a heavy chain DVD polypeptide, and a light chain DVD polypeptide, and two antigen binding sites.
  • each binding site comprises a heavy chain variable domain and a light chain variable domain with a total of 6 CDRs involved in antigen binding per antigen binding site.
  • scDVD- lgTM single chain dual variable domain immunoglobulin
  • scFvDVDIgTM single chain dual variable domain immunoglobulin
  • scDVD-lgTM are generally of the formula VH1 -(X1 )n-VH2-X2-VL1 -(X3)n-VL2, where VH1 is a first antibody heavy chain variable domain, X1 is a linker with the proviso that it is not a constant domain, VH2 is a second antibody heavy chain variable domain, X2 is a linker, VL1 is a first antibody light chain variable domain, X3 is a linker with the proviso that it is not a constant domain, VL2 is a second antibody light chain variable domain, and n is 0 or 1 , where the VH1 and VL1 , and the VH2 and VL2 respectively combine to form two functional antigen binding sites.
  • DVD-Fab or f DVD-lgTM refer to the antigen binding fragment of a DVD-lgTM molecule that is analogous to an antibody Fab fragment, f DVD-lgTM are described in U.S. S.N. 61 /746,663, incorporated herein by reference in its entirety.
  • fDVD-lgTM include a first polypeptide chain having the general formula VH1 -(X1 )n-VH2-C-(X2)n, wherein VH1 is a first heavy chain variable domain, X1 is a linker with the proviso that it is not a constant domain, VH2 is a second heavy chain variable domain, C is a heavy chain constant domain, X2 is a cell surface protein, and n is 0 or 1 , and wherein the amino acid sequences of VH1 , VH2 and/or X1 independently vary within the library.
  • the fDVD-lgTM also include a second
  • polypeptide chain having the general formula VL1 -(Y1 )n-VL2-C, wherein VL1 is a first light chain variable domain, Y1 is a linker with the proviso that it is not a constant domain, VL2 is a second light chain variable domain, C is a light chain constant domain, n is 0 or 1 , wherein the VH1 and VH2 of the first polypeptide chain and VL1 and VL2 of second polypeptide chains of the binding protein combine form two functional antigen binding sites.
  • the first and second polypeptide chains combine to form a fDVD- igTM
  • receptor DVD-lgTM constructs or “rDVD-lgTM” refer to DVD-lgTM constructs comprising at least one receptor-like binding domain. rDVD-lgTM are described in U.S. S.N. 61 /746,616, incorporated herein by reference in its entirety. Variable domains of the rDVD-lgTM molecule may include one immunoglobulin variable domain and one non- immunoglobulin variable domain such as a ligand binding domain of a receptor, or an active domain of an enzyme. rDVD-lgTM molecules may also comprise two or more non-lg domains (see PCT Publication No. WO 02/02773).
  • variable domains comprises a ligand binding domain of a receptor (RD).
  • receptor domain refers to the portion of a cell surface receptor, cytoplasmic receptor, nuclear receptor, or soluble receptor that functions to bind one or more receptor ligands or signaling molecules (e.g., toxins, hormones,
  • neurotransmitters cytokines, growth factors, or cell recognition molecules.
  • multi-specific and multivalent IgG-like molecules are capable of binding two or more proteins (e.g., antigens).
  • pDVD-lgTM are described in U.S. S.N. 61/746,617, incorporated herein by reference in its entirety.
  • pDVD-lgTM are disclosed which are generated by specifically modifying and adapting several concepts. These concepts include but are not limited to: (1 ) forming Fc heterodimer using CH3 "knobs-into-holes" design, (2) reducing light chain missing pairing by using CH1/CL cross-over, and (3) pairing two separate half IgG molecules at protein production stage using "reduction then oxidation" approach.
  • the binding protein of the invention is a
  • half-DVD-lg TM derived from a DVD-lgTM.
  • the half-DVD-lgTM preferably does not promote cross-linking observed with naturally occurring antibodies which can result in antigen clustering and undesirable activities. See U.S. patent publication number 20120201746 published August 9, 2012, and international publication number WO/2012/088302 published June 28, 2012, each of which is incorporated by reference herein in its entirety.
  • a pDVD-lgTM construct may be created by combining two halves of different DVD-lgTM molecules, or a half DVD-lgTM and half IgG molecule.
  • a pDVD-lgTM construct may be expressed from four unique constructs to create a monovalent, multi-specific molecules through the use of heavy chain CH3 knobs-into-holes design.
  • a pDVD-lgTM construct may contain two distinct light chains, and may utilize structural modifications on the Fc of one arm to ensure the proper pairing of the light chains with their respective heavy chains.
  • the heavy chain constant region CH1 may be swapped with a light chain constant region hCk on one Fab.
  • an entire light chain variable region, plus hCk may be swapped with a heavy chain variable region, plus CH1 .
  • pDVD-lgTM contain four polypeptide chains, namely, first, second, third and fourth polypeptide chains.
  • the first polypeptide chain may contain VD1 -(X1 )n-VD2-CH-(X2)n, wherein VD1 is a first heavy chain variable domain, VD2 is a second heavy chain variable domain, CH is a heavy chain constant domain, X1 is a linker with the proviso that it is not a constant domain, and X2 is an Fc region.
  • the second polypeptide chain may contain VD1 -(X1 )n- VD2-CL-(X2)n, wherein VD1 is a first light chain variable domain, VD2 is a second light chain variable domain, CL is a light chain constant domain, X1 is a linker with the proviso that it is not a constant domain, and X2 does not comprise an Fc region.
  • the third polypeptide chain may contain VD3-(X3)n-VD4-CL-(X4)n, wherein VD3 is a third heavy chain variable domain, VD4 is a fourth heavy chain variable domain, CL is a light chain constant domain, X3 is a linker with the proviso that it is not a constant domain, and X4 is an Fc region.
  • the fourth polypeptide chain may contain VD3- (X3)n-VD4-CH-(X4)n, wherein VD3 is a third light chain variable domain, VD4 is a fourth light chain variable domain, CH is a heavy chain constant domain, X3 is a linker with the proviso that it is not a constant domain, and X4 does not comprise an Fc region.
  • n is 0 or 1
  • the VD1 domains on the first and second polypeptide chains form one functional binding site for antigen A
  • the VD2 domains on the first and second polypeptide chains form one functional binding site for antigen B
  • the VD3 domains on the third and fourth polypeptide chains form one functional binding site for antigen C
  • the VD4 domains on the third and fourth polypeptide chains form one functional binding site for antigen D.
  • antigens A, B, C and D may be the same antigen, or they may each be a different antigen.
  • antigens A and B are the same antigen
  • antigens C and D are the same antigen.
  • mDVD-lgTM refers to a class of binding molecules wherein one binding arm has been rendered non-functional.
  • mDVD- lgTM are described in U.S. S.N. 61 /746,615, incorporated herein by reference in its entirety.
  • mDVD-lgTM possesses only one functional arm capable of binding a ligand.
  • the one functional arm may have one or more binding domains for binding to different ligands.
  • the ligand may be a peptide, a polypeptide, a protein, an aptamer, a polysaccharide, a sugar molecule, a carbohydrate, a lipid, an oligonucleotide, a polynucleotide, a synthetic molecule, an inorganic molecule, an organic molecule, and combinations thereof.
  • mDVD-lgTM contains four polypeptide chains, wherein two of the four polypeptide chains comprise VDH-(X1 )n-C-(X2)n.
  • VDH is a heavy chain variable domain
  • X1 is a linker with the proviso that it is not CH1
  • C is a heavy chain constant domain
  • X2 is an Fc region
  • n is 0 or 1 .
  • the other two of the four polypeptide chains comprise VDL-(X3)n-C-(X4)n, wherein VDL is a light chain variable domain, X3 is a linker with the proviso that it is not CH1 , C is a light chain constant domain, X4 does not comprise an Fc region, and n is 0 or 1 .
  • at least one of the four polypeptide chains comprises a mutation located in the variable domain, wherein the mutation inhibits the targeted binding between the specific antigen and the mutant binding domain.
  • the Fc regions of the two polypeptide chains that have a formula of VDH- (X1 )n-C-(X2)n may each contain a mutation, wherein the mutations on the two Fc regions enhance heterodimerization of the two polypeptide chains.
  • knobs-into-holes mutations may be introduced into these Fc regions to achieve heterodimerization of the Fc regions. See Atwell et al. J. Mol. Biol. 1997, 270: 26-35.
  • cross-over DVD-lgTM or “coDVD-lgTM” refers to a DVD-lgTM wherein the cross-over of variable domains is used to resolve the issue of affinity loss in the inner antigen-binding domains of some DVD-lgTM molecules.
  • coDVD-lgTM are described in U.S. S.N. 61 /746,619, incorporated herein by reference in its entirety.
  • cross-over dual-variable-domain (DVD) Igs are generated by crossing over light chain and the heavy chain variable domains of a dual-variable-domain (DVD) Ig or Ig like protein.
  • the length and sequence of the linkers linking the variable domains may be optimized for each format and antibody
  • sequence/structure (frameworks) to achieve desirable properties.
  • the disclosed concept and methodology may also be extended to Ig or Ig like proteins having more than two antigen binding domains.
  • antiidiotypic antibody refers to an antibody raised against the amino acid sequence of the antigen combining site of another antibody. Antiidiotypic antibodies may be administered to enhance an immune response against an antigen.
  • biological activity refers to any one or more biological properties of a molecule (whether present naturally as found in vivo, or provided or enabled by recombinant means). Biological properties include, but are not limited to, binding a receptor, inducing cell proliferation, inhibiting cell growth, inducing other cytokines, inducing apoptosis, and enzymatic activity.
  • neutralizing refers to counteracting the biological activity of an antigen when a binding protein specifically binds to the antigen.
  • the neutralizing binding protein binds to an antigen (e.g., a cytokine) and reduces biologically activity of the antigen by at least about 20%, 40%, 60%, 80%, 85% or more.
  • Specificity refers to the ability of a binding protein to selectively bind an antigen.
  • the term "specifically binds,” means that a binding protein or fragment thereof forms a complex with an antigen that is relatively stable under physiologic conditions.
  • Specific binding can be characterized by a dissociation constant of at least about 1 x10 "6 M or smaller. In other embodiments, the dissociation constant is at least about 1 x10 "7 M, 1 x10 "8 M , or 1 x10 "9 M.
  • Methods for determining whether two molecules specifically bind are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like.
  • the term "mammal” refers to any species that is a member of the class mammalia, including rodents, primates, dogs, cats, camelids and ungulates.
  • rodent refers to any species that is a member of the order rodentia including mice, rats, hamsters, gerbils and rabbits.
  • primaryate refers to any species that is a member of the order primates, including monkeys, apes and humans.
  • camelids refers to any species that is a member of the family camelidae including camels and llamas.
  • the term “ungulates” refers to any species that is a member of the superorder ungulata including cattle, horses and camelids.
  • Binding proteins are the strength of the interaction between a binding protein and an antigen, and is determined by the sequence of the CDRs of the binding protein as well as by the nature of the antigen, such as its size, shape, and/or charge. Binding proteins may be selected for affinities that provide desired therapeutic end-points while minimizing negative side-effects. Affinity may be measured using methods known to one skilled in the art (US 2009031 1253).
  • Potency refers to the ability of a binding protein to achieve a desired effect, and is a measurement of its therapeutic efficacy. Potency may be assessed using methods known to one skilled in the art (US 2009031 1253).
  • cross-reactivity refers to the ability of a binding protein to bind a target other than that against which it was raised.
  • a binding protein will bind its target tissue(s)/antigen(s) with an appropriately high affinity, but will display an appropriately low affinity for non-target normal tissues.
  • Individual binding proteins are generally selected to meet two criteria. (1 ) Tissue staining appropriate for the known expression of the antibody target. (2) Similar staining pattern between human and tox species (mouse and cynomolgus monkey) tissues from the same organ.
  • binding protein refers the specific in vitro or in vivo actions of a binding protein. Binding proteins may target several classes of antigens and achieve desired therapeutic outcomes through multiple mechanisms of action. Binding proteins may target soluble proteins, cell surface antigens, as well as extracellular protein deposits.
  • Binding proteins may agonize, antagonize, or neutralize the activity of their targets. Binding proteins may assist in the clearance of the targets to which they bind, or may result in cytotoxicity when bound to cells. Portions of two or more antibodies may be incorporated into a multivalent format to achieve distinct functions in a single binding protein molecule.
  • the in vitro assays and in vivo models used to assess biological function are known to one skilled in the art (US 2009031 1253).
  • a "stable" binding protein is one in which the binding protein essentially retains its physical stability, chemical stability and/or biological activity upon storage.
  • a multivalent binding protein that is stable in vitro at various temperatures for an extended period of time is desirable. Methods of stabilizing binding proteins and assessing their stability at various temperatures are known to one skilled in the art (US 2009031 1253).
  • solubility refers to the ability of a protein to remain dispersed within an aqueous solution.
  • solubility of a protein in an aqueous formulation depends upon the proper distribution of hydrophobic and hydrophilic amino acid residues, and therefore, solubility can correlate with the production of correctly folded proteins.
  • a person skilled in the art will be able to detect an increase or decrease in solubility of a binding protein using routine HPLC techniques and methods known to one skilled in the art (US 2009031 1253).
  • Binding proteins may be produced using a variety of host cells or may be produced in vitro, and the relative yield per effort determines the "production efficiency.” Factors influencing production efficiency include, but are not limited to, host cell type (prokaryotic or eukaryotic), choice of expression vector, choice of nucleotide sequence, and methods employed. The materials and methods used in binding protein production, as well as the measurement of production efficiency, are known to one skilled in the art (US 2009031 1253).
  • immunogenicity means the ability of a substance to induce an immune response.
  • Administration of a therapeutic binding protein may result in a certain incidence of an immune response.
  • Potential elements that might induce immunogenicity in a multivalent format may be analyzed during selection of the parental antibodies, and steps to reduce such risk can be taken to optimize the parental antibodies prior to incorporating their sequences into a multivalent binding protein format.
  • label and “detectable label” mean a moiety attached to a member of a specific binding pair, such as an antibody or its analyte to render a reaction (e.g., binding) between the members of the specific binding pair, detectable.
  • the labeled member of the specific binding pair is referred to as “detectably labeled.”
  • label binding protein refers to a protein with a label incorporated that provides for the identification of the binding protein.
  • the label is a detectable marker that can produce a signal that is detectable by visual or instrumental means, e.g., incorporation of a radiolabeled amino acid or attachment to a polypeptide of biotinyl moieties that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods).
  • marked avidin e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods.
  • labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e.g., 3 H 14 C 35 S, 90 Y, "Tc, 111 In, 125 l, 131 1, 177 Lu, 166 Ho, or 153 Sm); chromogens, fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradish peroxidase, luciferase, alkaline phosphatase); chemiluminescent markers; biotinyl groups; predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags); and magnetic agents, such as gadolinium chelates.
  • radioisotopes or radionuclides e.g., 3 H 14 C 35 S, 90 Y, "Tc
  • labels commonly employed for immunoassays include moieties that produce light, e.g., acridinium compounds, and moieties that produce fluorescence, e.g., fluorescein.
  • the moiety itself may not be detectably labeled but may become detectable upon reaction with yet another moiety.
  • conjugate refers to a binding protein, such as an antibody, that is chemically linked to a second chemical moiety, such as a therapeutic or cytotoxic agent.
  • agent includes a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials.
  • the therapeutic agents or cytotoxic agents include, but are not limited to, pertussis toxin, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1 -dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof.
  • the conjugate antibody may be a detectably labeled antibody used as the detection antibody.
  • crystal and “crystallized” refer to a binding protein (e.g., an antibody), or antigen binding portion thereof, that exists in the form of a crystal.
  • Crystals are one form of the solid state of matter, which is distinct from other forms such as the amorphous solid state or the liquid crystalline state. Crystals are composed of regular, repeating, three-dimensional arrays of atoms, ions, molecules (e.g., proteins such as antibodies), or molecular assemblies (e.g., antigen/antibody complexes). These three- dimensional arrays are arranged according to specific mathematical relationships that are well-understood in the field. The fundamental unit, or building block, that is repeated in a crystal is called the asymmetric unit.
  • Repetition of the asymmetric unit in an arrangement that conforms to a given, well-defined crystal log raphic symmetry provides the "unit cell" of the crystal. Repetition of the unit cell by regular translations in all three dimensions provides the crystal. See Giege, R. and Ducruix, A. Barrett, CRYSTALLIZATION OF NUCLEIC ACIDS AND PROTEINS, A PRACTICAL APPROACH, 2nd ea., pp. 20 1 -16, Oxford University Press, New York, New York, (1999).
  • vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • plasmid refers to a circular double stranded DNA loop into which additional DNA segments may be ligated.
  • viral vector refers to a viral vector, wherein additional DNA segments may be ligated into the viral genome.
  • Other vectors include RNA vectors. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
  • vectors e.g., non-episomal mammalian vectors
  • vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
  • Certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “recombinant expression vectors” (or simply, “expression vectors”).
  • expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
  • plasmid and vector may be used interchangeably as the plasmid is the most commonly used form of vector.
  • expression vectors are also included, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.
  • viral vectors e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses
  • a group of pHybE vectors (US Patent Application Serial No. 61 /021 ,282) were used for parental antibody and DVD-binding protein cloning.
  • V1 derived from pJP183; pHybE-hCgl ,z,non-a V2
  • V2 derived from pJP191 ; pHybE-hCk V3, was used for cloning of antibody and DVD light chains with a kappa constant region.
  • V3 derived from pJP1 92; pHybE-hCI V2, was used for cloning of antibody and DVDs light chains with a lambda constant region.
  • V4 built with a lambda signal peptide and a kappa constant region, was used for cloning of DVD light chains with a lambda-kappa hybrid V domain.
  • V5, built with a kappa signal peptide and a lambda constant region, was used for cloning of DVD light chains with a kappa-lambda hybrid V domain.
  • V7 derived from pJP183; pHybE-hCgl , ⁇ , ⁇ - a V2, was used for cloning of antibody and DVD heavy chains with a (234,235 AA) mutant constant region.
  • the terms "recombinant host cell” or "host cell” refer to a cell into which exogenous DNA has been introduced. Such terms refer not only to the particular subject cell, but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell” as used herein.
  • host cells include prokaryotic and eukaryotic cells.
  • eukaryotic cells include protist, fungal, plant and animal cells.
  • host cells include but are not limited to the prokaryotic cell line E.Coli;
  • transfection encompasses a variety of techniques commonly used for the introduction of exogenous nucleic acid (e.g., DNA) into a host cell, e.g., electroporation, calcium-phosphate precipitation, DEAE-dextran transfection and the like.
  • exogenous nucleic acid e.g., DNA
  • electroporation e.g., electroporation, calcium-phosphate precipitation, DEAE-dextran transfection and the like.
  • cytokine refers to a protein released by one cell population that acts on another cell population as an intercellular mediator.
  • cytokine includes proteins from natural sources or from recombinant cell culture and biologically active equivalents of the native sequence cytokines.
  • biological sample means a quantity of a substance from a living thing or formerly living thing.
  • substances include, but are not limited to, blood, (e.g., whole blood), plasma, serum, urine, amniotic fluid, synovial fluid, endothelial cells, leukocytes, monocytes, other cells, organs, tissues, bone marrow, lymph nodes and spleen.
  • a component refers to an element of a composition.
  • a component may be a capture antibody, a detection or conjugate antibody, a control, a calibrator, a series of calibrators, a sensitivity panel, a container, a buffer, a diluent, a salt, an enzyme, a co-factor for an enzyme, a detection reagent, a pretreatment reagent/solution, a substrate (e.g., as a solution), a stop solution, and the like that can be included in a kit for assay of a test sample.
  • a “component” can include a polypeptide or other analyte as above, that is immobilized on a solid support, such as by binding to an anti-analyte (e.g., anti-polypeptide) antibody.
  • Some components can be in solution or lyophilized for reconstitution for use in an assay.
  • Control refers to a composition known to not analyte ("negative control") or to contain analyte ("positive control”).
  • a positive control can comprise a known concentration of analyte.
  • Control positive control
  • calibrator may be used interchangeably herein to refer to a composition comprising a known concentration of analyte.
  • a "positive control” can be used to establish assay performance characteristics and is a useful indicator of the integrity of reagents (e.g., analytes).
  • Predetermined cutoff and predetermined level refer generally to an assay cutoff value that is used to assess diagnostic/prognostic/therapeutic efficacy results by comparing the assay results against the predetermined cutoff/level, where the
  • predetermined cutoff/level already has been linked or associated with various clinical parameters (e.g., severity of disease, progression/nonprogression/improvement, etc.). While the present disclosure may provide exemplary predetermined levels, it is well-known that cutoff values may vary depending on the nature of the immunoassay (e.g., antibodies employed, etc.). It further is well within the ordinary skill of one in the art to adapt the disclosure herein for other immunoassays to obtain immunoassay-specific cutoff values for those other immunoassays based on this disclosure. Whereas the precise value of the predetermined cutoff/level may vary between assays, correlations as described herein (if any) may be generally applicable.
  • Pretreatment reagent e.g., lysis, precipitation and/or solubilization reagent, as used in a diagnostic assay as described herein is one that lyses any cells and/or solubilizes any analyte that is/are present in a test sample. Pretreatment is not necessary for all samples, as described further herein. Among other things, solubilizing the analyte (e.g., polypeptide of interest) may entail release of the analyte from any endogenous binding proteins present in the sample.
  • a pretreatment reagent may be homogeneous (not requiring a separation step) or heterogeneous (requiring a separation step). With use of a
  • heterogeneous pretreatment reagent there is removal of any precipitated analyte binding proteins from the test sample prior to proceeding to the next step of the assay.
  • “Quality control reagents” in the context of immunoassays and kits described herein, include, but are not limited to, calibrators, controls, and sensitivity panels.
  • a "calibrator” or “standard” typically is used (e.g., one or more, such as a plurality) in order to establish calibration (standard) curves for interpolation of the concentration of an analyte, such as an antibody or an analyte.
  • a single calibrator which is near a predetermined positive/negative cutoff, can be used.
  • Multiple calibrators i.e., more than one calibrator or a varying amount of calibrator(s) can be used in conjunction so as to comprise a "sensitivity panel.”
  • specific binding partner is a member of a specific binding pair.
  • a specific binding pair comprises two different molecules that specifically bind to each other through chemical or physical means. Therefore, in addition to antigen and antibody specific binding, other specific binding pairs can include biotin and avidin (or streptavidin), carbohydrates and lectins, complementary nucleotide sequences, effector and receptor molecules, cofactors and enzymes, enzyme inhibitors and enzymes, and the like.
  • specific binding pairs can include members that are analogs of the original specific binding members, for example, an analyte-analog.
  • Immunoreactive specific binding members include antigens, antigen fragments, and antibodies, including monoclonal and polyclonal antibodies as well as complexes, fragments, and variants (including fragments of variants) thereof, whether isolated or recombinantly produced.
  • Fc region defines the C-terminal region of an immunoglobulin heavy chain, which may be generated by papain digestion of an intact antibody.
  • the Fc region may be a native sequence Fc region or a variant Fc region.
  • the Fc region of an immunoglobulin generally comprises two constant domains, a CH2 domain and a CH3 domain, and optionally comprises a CH4 domain. Replacements of amino acid residues in the Fc portion to alter antibody effector function are known in the art (e.g., US Patent Nos. 5,648,260 and 5,624,821 ).
  • the Fc region mediates several important effector functions, e.g., cytokine induction, antibody dependent cell mediated cytotoxicity (ADCC), phagocytosis, complement dependent cytotoxicity (CDC), and half-life/ clearance rate of antibody and antigen-antibody complexes.
  • cytokine induction antibody dependent cell mediated cytotoxicity (ADCC)
  • phagocytosis phagocytosis
  • complement dependent cytotoxicity cytotoxicity
  • half-life/ clearance rate of antibody and antigen-antibody complexes are desirable for a therapeutic immunoglobulin but in other cases might be unnecessary or even deleterious, depending on the therapeutic objectives.
  • the term "antigen-binding portion" of a binding protein means one or more fragments of a binding protein (e.g., an antibody) that retain the ability to specifically bind to an antigen.
  • the antigen-binding portion of a binding protein can be performed by fragments of a full-length antibody, as well as bispecific, dual specific, or multi-specific formats;
  • binding fragments encompassed within the term "antigen-binding portion" of an binding protein include (i) an Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) an F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) an Fd fragment consisting of the VH and CH1 domains; (iv) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment, which comprises a single variable domain; and (vi) an isolated
  • single chain Fv complementarity determining region
  • single chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody.
  • antigen-binding portion of an antibody.
  • single chain antibodies also include "linear antibodies” comprising a pair of tandem Fv segments (VH-CH1 -VH-CH1 ) which, together with complementary light chain polypeptides, form a pair of antigen binding regions.
  • multivalent binding protein means a binding protein comprising two or more antigen binding sites.
  • the multivalent binding protein is engineered to have three or more antigen binding sites, and is not a naturally occurring antibody.
  • multispecific binding protein refers to a binding protein capable of binding two or more related or unrelated targets.
  • the dual variable domain (DVD) binding proteins provided herein comprise two or more antigen binding sites and are tetravalent or multivalent binding proteins.
  • linker means an amino acid residue or a polypeptide comprising two or more amino acid residues joined by peptide bonds that are used to link two polypeptides (e.g., two VH or two VL domains).
  • linker polypeptides are well known in the art (see, e.g., Holliger et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak et al. (1994) Structure 2:1 121 -1 123).
  • Kabat numbering “Kabat definitions” and “Kabat labeling” are used interchangeably herein. These terms, which are recognized in the art, refer to a system of numbering amino acid residues which are more variable (i.e., hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen binding portion thereof (Kabat et al. (1971 ) Ann. NY Acad. Sci. 190:382-391 and, Kabat et al. (1991 ) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91 -3242).
  • the hypervariable region ranges from amino acid positions 31 to 35 for CDR1 , amino acid positions 50 to 65 for CDR2, and amino acid positions 95 to 102 for CDR3.
  • the hypervariable region ranges from amino acid positions 24 to 34 for CDR1 , amino acid positions 50 to 56 for CDR2, and amino acid positions 89 to 97 for CDR3.
  • CDR means a complementarity determining region within an immunoglobulin variable region sequence. There are three CDRs in each of the variable regions of the heavy chain and the light chain, which are designated CDR1 , CDR2 and CDR3, for each of the heavy and light chain variable regions.
  • CDR set refers to a group of three CDRs that occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs have been defined differently according to different systems. The system described by Kabat (Kabat et al. (1987) and (1991 )) not only provides an unambiguous residue numbering system applicable to any variable region of an antibody, but also provides precise residue boundaries defining the three CDRs.
  • CDRs may be referred to as Kabat CDRs.
  • Chothia and coworkers Chothia and Lesk (1987) J. Mol. Biol. 196:901 -917; Chothia et al. (1989) Nature 342:877-883) found that certain sub- portions within Kabat CDRs adopt nearly identical peptide backbone conformations, despite having great diversity at the level of amino acid sequence. These sub-portions were designated as L1 , L2 and L3 or H1 , H2 and H3 where the "L” and the "H” designates the light chain and the heavy chain regions, respectively. These regions may be referred to as Chothia CDRs, which have boundaries that overlap with Kabat CDRs.
  • epitope means a region of an antigen that is bound by a binding protein, e.g., a polypeptide and/or other determinant capable of specific binding to an immunoglobulin or T-cell receptor.
  • epitope determinants include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl, or sulfonyl, and, in certain embodiments, may have specific three dimensional structural characteristics, and/or specific charge characteristics.
  • an epitope comprises the amino acid residues of a region of an antigen (or fragment thereof) known to bind to the complementary site on the specific binding partner.
  • An antigenic fragment can contain more than one epitope.
  • a binding protein specifically binds an antigen when it recognizes its target antigen in a complex mixture of proteins and/or macromolecules. Binding proteins "bind to the same epitope” if the antibodies cross-compete (one prevents the binding or modulating effect of the other). In addition, structural definitions of epitopes (overlapping, similar, identical) are informative; and functional definitions encompass structural (binding) and functional (modulation, competition) parameters. Different regions of proteins may perform different functions. For example specific regions of a cytokine interact with its cytokine receptor to bring about receptor activation whereas other regions of the protein may be required for stabilizing the cytokine.
  • the cytokine may be targeted with a binding protein that binds specifically to the receptor interacting region(s), thereby preventing the binding of its receptor.
  • a binding protein may target the regions responsible for cytokine stabilization, thereby designating the protein for degradation.
  • Pharmacokinetics refers to the process by which a drug is absorbed, distributed, metabolized, and excreted by an organism.
  • parent monoclonal antibodies with similarly desired pharmacokinetic profiles are selected.
  • the PK profiles of the selected parental monoclonal antibodies can be easily determined in rodents using methods known to one skilled in the art (US 2009031 1253).
  • Bioavailability refers to the amount of active drug that reaches its target following administration. Bioavailability is function of several of the previously described properties, including stability, solubility, immunogenicity and pharmacokinetics, and can be assessed using methods known to one skilled in the art (US 2009031 1253).
  • surface plasmon resonance means an optical phenomenon that allows for the analysis of real-time biospecific interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIAcore® system (BIAcore International AB, a GE Healthcare company, Uppsala, Sweden and Piscataway, NJ). For further descriptions, see Jonsson et al. (1993) Ann. Biol. Clin. 51 :19-26.
  • K on means the on rate constant for association of a binding protein (e.g., an antibody or
  • DVD-lgTM to the antigen to form the, e.g., DVD-lgTM /antigen complex.
  • K on also means "association rate constant", or “ka”, as is used interchangeably herein. This value indicating the binding rate of a binding protein to its target antigen or the rate of complex formation between a binding protein, e.g., an antibody, and antigen also is shown by the equation below:
  • K 0 ff means the off rate constant for dissociation, or "dissociation rate constant", of a binding protein (e.g., an antibody or DVD-lgTM) from the, e.g., DVD-lgTM /antigen complex as is known in the art.
  • This value indicates the dissociation rate of a binding protein, e.g., an antibody, from its target antigen or separation of Ab-Ag complex over time into free antibody and antigen as shown by the equation below:
  • K d and "equilibrium dissociation constant” means the value obtained in a titration measurement at equilibrium, or by dividing the dissociation rate constant (K 0 ff) by the association rate constant (K on ).
  • the association rate constant, the dissociation rate constant and the equilibrium dissociation constant are used to represent the binding affinity of a binding protein (e.g., an antibody or DVD-lgTM) to an antigen.
  • association and dissociation rate constants are well known in the art. Using fluorescence-based techniques offers high sensitivity and the ability to examine samples in physiological buffers at equilibrium. Other experimental approaches and instruments such as a BIAcore® (biomolecular interaction analysis) assay, can be used (e.g., instrument available from BIAcore International AB, a GE Healthcare company, Uppsala, Sweden). Additionally, a KinExA® (Kinetic Exclusion Assay) assay, available from Sapidyne Instruments (Boise, Idaho), can also be used.
  • BIAcore® biological interaction analysis
  • variant means a polypeptide that differs from a given polypeptide in amino acid sequence by the addition (e.g., insertion), deletion, or conservative substitution of amino acids, but that retains the biological activity of the given polypeptide (e.g., a variant Tf R antibody can compete with anti-Tf R antibody for binding to Tf R).
  • a conservative substitution of an amino acid i.e., replacing an amino acid with a different amino acid of similar properties (e.g., hydrophilicity and degree and distribution of charged regions) is recognized in the art as typically involving a minor change.
  • hydropathic index of amino acids as understood in the art (see, e.g., Kyte et al. (1982) J. Mol. Biol. 157: 105-132).
  • the hydropathic index of an amino acid is based on a consideration of its hydrophobicity and charge. It is known in the art that amino acids of similar hydropathic indexes in a protein can be substituted and the protein still retains protein function. In one aspect, amino acids having hydropathic indexes of ⁇ 2 are substituted.
  • the hydrophilicity of amino acids also can be used to reveal substitutions that would result in proteins retaining biological function.
  • hydrophilicity of amino acids in the context of a peptide permits calculation of the greatest local average hydrophilicity of that peptide, a useful measure that has been reported to correlate well with antigenicity and immunogenicity (see, e.g., US Patent No. 4,554,101 ).
  • Substitution of amino acids having similar hydrophilicity values can result in peptides retaining biological activity, for example immunogenicity, as is understood in the art.
  • substitutions are performed with amino acids having hydrophilicity values within ⁇ 2 of each other. Both the hydrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid.
  • amino acid substitutions that are compatible with biological function are understood to depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicity, hydrophilicity, charge, size, and other properties.
  • variant also includes polypeptide or fragment thereof that has been differentially processed, such as by proteolysis, phosphorylation, or other post-translational modification, yet retains its biological activity or antigen reactivity, e.g., the ability to bind to Tf R.
  • variant encompasses fragments of a variant unless otherwise defined.
  • a variant may be 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91 %, 90%, 89%, 88%, 87%, 86%,85%, 84%, 83%, 82%, 81 %, 80%, 79%, 78%, 77%, 76%, or 75% identical to the wildtype sequence.
  • binding proteins capable of binding TfR and methods of making the same are provided.
  • the binding protein can be generated using various techniques. Expression vectors, host cell and methods of generating the binding protein are provided and are well known in the art.
  • variable domains of the DVD binding protein can be obtained from parent antibodies, including polyclonal Abs and mAbs capable of binding antigens of interest. These antibodies may be naturally occurring or may be generated by recombinant technology.
  • the person of ordinary skill in the art is well familiar with many methods for producing antibodies, including, but not limited to using hybridoma techniques, selected lymphocyte antibody method (SLAM), use of a phage, yeast, or RNA-protein fusion display or other library, immunizing a non-human animal comprising at least some of the human immunoglobulin locus, and preparation of chimeric, CDR-grafted, and humanized antibodies. See, e.g., US Patent Publication No. 20090311253 A1 .
  • Variable domains may also be prepared using affinity maturation techniques.
  • An embodiment comprising selecting parent antibodies with at least one or more properties desired in the DVD binding protein molecule.
  • the desired property is one or more antibody parameters, such as, for example, antigen specificity, affinity to antigen, potency, biological function, epitope recognition, stability, solubility, production efficiency, immunogenicity, pharmacokinetics, bioavailability, tissue cross reactivity, or orthologous antigen binding. See, e.g., US Patent Publication No. 2009031 1253.
  • the binding protein may be designed such that two different light chain variable domains (VL) from the two different parent monoclonal antibodies are linked in tandem directly or via a linker by recombinant DNA techniques, followed by the light chain constant domain CL.
  • the heavy chain comprises two different heavy chain variable domains (VH) linked in tandem, directly or via a linker, followed by the constant domain CH1 and Fc region ( Figure 1 ).
  • variable domains can be obtained using recombinant DNA techniques from parent antibodies generated by any one of the methods described herein.
  • the variable domain is a murine heavy or light chain variable domain.
  • the variable domain is a CDR grafted or a humanized variable heavy or light chain domain.
  • the variable domain is a human heavy or light chain variable domain.
  • the linker sequence may be a single amino acid or a polypeptide sequence.
  • the choice of linker sequences is based on crystal structure analysis of several Fab molecules.
  • DVD binding proteins were generated using N-terminal 5-6 amino acid residues, or 1 1 -12 amino acid residues, of CL or CH1 as a linker in the light chain and heavy chains, respectively.
  • the N-terminal residues of CL or CH1 domains can adopt a loop conformation without strong secondary structures, and therefore can act as flexible linkers between the two variable domains.
  • the N-terminal residues of CL or CH1 domains are natural extension of the variable domains, as they are part of the Ig sequences, and therefore their use minimizes to a large extent any immunogenicity potentially arising from the linkers and junctions.
  • any of the heavy chain, light chain, two chain, or four chain embodiments includes at least one linker comprising AKTTPKLEEGEFSEAR (SEQ ID NO: 1 ); AKTTPKLEEGEFSEARV (SEQ ID NO: 2); AKTTPKLGG (SEQ ID NO: 3); SAKTTPKLGG (SEQ ID NO: 4); SAKTTP (SEQ ID NO: 5); RADAAP (SEQ ID NO: 6);
  • RADAAPTVS SEQ ID NO: 7
  • RADAAAAGGPGS SEQ ID NO: 8
  • RADAAAA(G 4 S) 4 SEQ ID NO: 9
  • SAKTTPKLEEGEFSEARV SEQ ID NO: 10
  • ADAAP SEQ ID NO: 1 1
  • ADAAPTVSIFPP SEQ ID NO: 12
  • TVAAP SEQ ID NO: 13
  • TVAAPSVFIFPP SEQ ID NO: 14
  • QPKAAP SEQ ID NO: 15
  • QPKAAPSVTLFPP SEQ ID NO: 16
  • AKTTPP SEQ ID NO: 17
  • AKTTPPSVTPLAP SEQ ID NO: 18
  • AKTTAP SEQ ID NO: 19
  • AKTTAPSVYPLAP SEQ ID NO: 20
  • ASTKGP SEQ ID NO: 21
  • ASTKGPSVFPLAP SEQ ID NO: 22
  • GGGGSGGGGSGGGGS SEQ ID NO: 23
  • GENKVEYAPALMALS SEQ ID NO: 24
  • GPAKELTPLKEAKVS SEQ ID NO: 25
  • G H E AAAVMQVQ YP AS SEQ ID NO: 26
  • TVAAPSVFIFPPTVAAPSVFIFPP SEQ ID NO: 27
  • X2 is an Fc region. In another embodiment, X2 is a variant Fc region.
  • the linker comprises GS-H1 0 (Chain H)
  • the linker comprises GS-L10 (Chain L) GGSGGGGSG (SEQ ID NO:179). In various embodiments, the linker comprises HG-short (Chain H) ASTKGP (SEQ ID NO:21 ). In various embodiments, the linker comprises LK-long (Chain L) TVAAPSVFIFPP (SEQ ID NO: 14). For example SEQ I D NOs: 21 and 178 are located on a variable heavy chain or domain of a DVD-lg. For example SEQ ID NOs: 14 and 1 79 are located on a variable light chain or domain of a DVD-lg.
  • linker sequences may include any sequence of any length of a CL/CH1 domain but not all residues of a CL/CH1 domain ; for example the first 5-12 amino acid residues of a CL/CH1 domain; the light chain linkers can be from CK or CA; and the heavy chain linkers can be derived from CH1 of any isotype, including Cy1 , Cy2, Cy3, Cy4, Ca1 , Ca2, C5, Cz, and ⁇ .
  • Linker sequences may also be derived from other proteins such as Ig-like proteins (e.g., TCR, FcR, KIR); G/S based sequences (e.g. , G4S repeats; SEQ I D NO: 29); hinge region-derived sequences; and other natural sequences from other proteins.
  • a constant domain is linked to the two linked variable domains using recombinant DNA techniques.
  • a sequence comprising linked heavy chain variable domains is linked to a heavy chain constant domain and a sequence comprising linked light chain variable domains is linked to a light chain constant domain.
  • the constant domains are human heavy chain constant domains and human light chain constant domains respectively.
  • the DVD heavy chain is further linked to an Fc region.
  • the Fc region may be a native sequence Fc region or a variant Fc region.
  • the Fc region is a human Fc region.
  • the Fc region includes Fc region from lgG1 , lgG2, lgG3, lgG4, IgA, IgM, IgE, or IgD.
  • two heavy chain DVD polypeptides and two light chain DVD polypeptides are combined to form a DVD binding protein.
  • Tables 1 A-1 C list amino acid sequences of VH and VL regions of exemplary antibodies useful for treating disease.
  • a DVD comprising at least two of the VH and/or VL regions listed in Table 1 , in any orientation, is provided.
  • VD1 and VD2 are independently chosen. Therefore, in some embodiments, VD1 and VD2 comprise the same SEQ I D NO and, in other embodiments, VD1 and VD2 comprise different SEQ ID NOS.
  • VH and VL domain sequences comprise complementarity determining regions (CDRs) and framework sequences that are either known in the art or readily discernible using methods known in the art.
  • CDRs complementarity determining regions
  • framework sequences that are either known in the art or readily discernible using methods known in the art.
  • one or more of these CDRs and/or framework sequences are replaced, without loss of function, by other CDRs and/or framework sequences from binding proteins that are known in the art to bind to the same antigen.
  • Specific DVD binding proteins capable of binding specific targets, and methods of making the same, is provided in the Examples section below.
  • the binding proteins provided herein may be produced by any of a number of techniques known in the art. For example, expression from host cells, wherein expression vector(s) encoding the DVD heavy and DVD light chains is (are) transfected into a host cell by standard techniques. Although it is possible to express the DVD binding proteins provided herein in either prokaryotic or eukaryotic host cells, DVD binding proteins are expressed in eukaryotic cells, for example, mammalian host cells, because such eukaryotic cells (and in particular mammalian cells) are more likely than prokaryotic cells to assemble and secrete a properly folded and immunologically active DVD binding protein.
  • a recombinant expression vector encoding both the DVD heavy chain and the DVD light chain is introduced into dhfr- CHO cells by calcium phosphate-mediated transfection.
  • the DVD heavy and light chain genes are each operatively linked to CMV enhancer/AdMLP promoter regulatory elements to drive high levels of transcription of the genes.
  • the recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been transfected with the vector using methotrexate selection/amplification. The selected transformant host cells are cultured to allow for expression of the DVD heavy and light chains and intact DVD protein is recovered from the culture medium.
  • Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select for transformants, culture the host cells and recover the DVD protein from the culture medium.
  • a method of synthesizing a DVD protein provided herein by culturing a host cell provided herein in a suitable culture medium until a DVD protein is synthesized is also provided. The method can further comprise isolating the DVD protein from the culture medium.
  • DVD binding protein An important feature of DVD binding protein is that it can be produced and purified in a similar way as a conventional antibody.
  • the production of DVD binding protein results in a homogeneous, single major product with desired dual-specific activity, without the need for sequence modification of the constant region or chemical modifications.
  • Other previously described methods to generate "bi-specific”, “multi-specific”, and “multi-specific multivalent” full length binding proteins can lead to the intracellular or secreted production of a mixture of assembled inactive, mono-specific, multi-specific, multivalent, full length binding proteins, and multivalent full length binding proteins with a combination of different binding sites.
  • At least 50%, at least 75% and at least 90% of the assembled, and expressed dual variable domain immunoglobulin molecules are the desired dual-specific tetravalent protein, and therefore possess enhanced commercial utility.
  • a method to express a dual variable domain light chain and a dual variable domain heavy chain in a single cell leading to a single primary product of a "dual-specific tetravalent full length binding protein" is provided.
  • Methods of expressing a dual variable domain light chain and a dual variable domain heavy chain in a single cell leading to a "primary product" of a "dual-specific tetravalent full length binding protein", where the "primary product" is more than 50%, such as more than 75% and more than 90%, of all assembled protein, comprising a dual variable domain light chain and a dual variable domain heavy chain are provided.
  • cassettes can be used to construct binding proteins that specifically bind to an antigen expressed on brain vascular epithelium of a subject that facilitates uptake of the binding protein into the brain of the subject.
  • the formula for these binding proteins is
  • Out1 is a first outer binding domain and In1 is a first inner binding domain.
  • the inner binding domain represents a binding domain positioned closer to the Fc region of a DVD-lgTM than the outer binding domain.
  • the outer binding domain is located at or near the N- terminal end of the binding protein while the inner binding domain is located at or near the C-terminal end of the binding protein.
  • X1 is a linker. According to some embodiments, X1 is any of the linkers defined herein. According to other specific embodiments, X1 has a sequence comprising the amino acid sequences of SEQ ID NO:14 or 21 when Out1 specifically binds an antigen expressed on brain vascular epithelium of a subject that facilitates uptake of the binding protein into the brain of the subject and In1 does not specifically bind said antigen, while X1 has a sequence comprising the amino acid sequence of SEQ ID NO:178 or 179 when In 1 specifically binds an antigen expressed on brain vascular epithelium of a subject that facilitates uptake of the binding protein into the brain of the subject and Out1 does not specifically bind said antigen.
  • X2 is an Fc region. The values of m and n in Formula I are 0 or 1 . In certain
  • X1 when n is 0 X1 is X1 comprises the amino acid sequence of SEQ ID NO:14 or 179 depending on whether Out1 or In1 specifically binds an antigen expressed on brain vascular epithelium of a subject that facilitates uptake of the binding protein into the brain of the subject.
  • n when n is 1 X1 comprises the amino acid sequences of SEQ ID NO:21 or 178 depending on whether Out1 or In1 specifically binds said antigen.
  • Out1 When Out1 is used to specifically bind an antigen expressed on brain vascular epithelium of a subject that facilitates uptake of the binding protein into the brain it does not need to have as high an affinity as when In1 is used.
  • an antigen expressed on brain vascular epithelium of a subject that facilitates uptake of the binding protein into the brain it does not need to have as high an affinity as when In1 is used.
  • the binding affinity that Out 1 has for said antigen is lower than if In1 were to bind said antigen.
  • the EC50 of the binding is greater than about 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 nM.
  • the EC50 of the binding is between about 1 and 10 nM, 2 and 8 nM, 3 and 10 nM, 3 and 9 nM, 3 and 8 nM, 3 and 7 nM, 3 and 6 nM, 3 and 5 nM, 3 and 4 nM, 4 and 10 nM or 5 and 10nM
  • Out1 when Out1 specifically binds transferrin receptor (Tf R) Out1 has an affinity for TfR that is lower than if In1 were to specifically bind to TfR.
  • the EC50 of the binding is greater than about 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 nM. In other embodiments, the EC50 is greater than about 3 nM.
  • the EC50 of the binding is between about 1 and 10 nM, 2 and 8 nM, 3 and 10 nM, 3 and 9 nM, 3 and 8 nM, 3 and 7 nM, 3 and 6 nM, 3 and 5 nM, 3 and 4 nM, 4 and 10 nM or 5 and 10nM. In other embodiments, the EC50 is between about 3 and 10 nM, 3 and 9 nM, 3 and 8 nM, 3 and 7 nM, 3 and 6 nM, 3 and 5 nM, or 3 and 4 nM. In certain embodiments, Out1 comprises the amino acid sequence of SEQ ID NO:56.
  • In1 when Out1 specifically binds an antigen expressed on brain vascular epithelium of a subject that facilitates uptake of the binding protein into the brain, In1 binds another antigen.
  • This antigen can be selected from CGRP, TNFa, RGMA, Substance P, Bradykinin, Nav1.7, LPA, P2X3, NGF, Abeta; BACE1 ; IL- ⁇ ⁇ ; IGF1 ,or 2; IL-18; IL-6; RAGE; NGF; EGFR; cMet, Her -2 and CD-20.
  • In1 When In1 is used to specifically bind an antigen expressed on brain vascular epithelium of a subject that facilitates uptake of the binding protein into the brain it needs to have a higher affinity than when Out1 is used.
  • the binding affinity that In1 has for said antigen is higher than if Out1 were to bind said antigen.
  • the EC50 of the binding is less than about 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 nM.
  • the EC50 of the binding is between about 1 and 0.001 nM, 2 and 0.001 nM, 3 and 0.0001 nM, 3 and 0.001 nM, 3 and 0.01 nM, 3 and 0.1 nM, 3 and 1 nM, 3 and 5 nM, 3 and 10 nM, 4 and 10 nM or 5 and 10nM.
  • In 1 when Out1 specifically binds transferrin receptor (Tf R) In 1 has an affinity for TfR that is higher than if Out1 were to specifically bind to TfR.
  • Tf R transferrin receptor
  • the EC50 of the binding is less than about 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 nM. In other embodiments, the EC50 is less than about 3 nM.
  • the EC50 of the binding is between about 1 and 0.001 nM, 2 and 0.001 nM, 3 and 0.0001 nM, 3 and 0.001 nM, 3 and 0.01 nM, 3 and 0.1 nM, 3 and 1 nM, 3 and 5 nM, 3 and 10 nM, 4 and 10 nM or 5 and 10nM. In other embodiments, the EC50 is between about 3 and 0.0001 nM, 3 and 0.001 nM, 3 and 0.01 nM, 3 and 0.1 nM, 3 and 1 nM, 3 and 5 nM or 3 and 10 nM.
  • In1 comprises the amino acid sequence of SEQ ID NO:36.
  • In1 when In1 specifically binds an antigen expressed on brain vascular epithelium of a subject that facilitates uptake of the binding protein into the brain, Out1 binds another antigen.
  • This antigen can be selected from CGRP, TNFa, RGMA, Substance P, Bradykinin, Nav1.7, LPA, P2X3, NGF, Abeta; BACE1 ; IL- ⁇ ⁇ ; IGF1 ,or 2; IL-18; IL-6; RAGE; NGF; EGFR; cMet, Her -2 and CD-20.
  • a binding protein may comprise a second binding protein.
  • the formula for this second binding protein is
  • Out2 is a second outer binding domain and In2 is a second inner binding domain.
  • the inner binding domain represents a binding domain positioned closer to the Fc region of a DVD- IgTM than the outer binding domain.
  • the outer binding domain is located at or near the N-terminal end of the binding protein while the inner binding domain is located at or near the C-terminal end of the binding protein.
  • X1 and X2 are as defined in Formula I, above.
  • Out2 and In2 operate in the same manner as Out1 and In1 described above.
  • This second binding protein can be associated with a first binding protein to form a binding polypeptide such as a DVD-lgTM.
  • n is 1 and in the second binding protein n is 0.
  • both Out1 and Out2 bind an antigen expressed on brain vascular epithelium of a subject that facilitates uptake of the binding protein into the brain of the subject.
  • both In 1 and In2 bind said antigen.
  • Out1 and In2 or Out2 and In1 bind said antigen.
  • Out2 comprises the amino acid sequence of SEQ ID NO:37.
  • In2 comprises the amino acid sequence of SEQ ID NO:57.
  • the binding proteins provided herein can be used to detect the antigens (e.g., in a biological sample, such as serum or plasma), using a conventional immunoassay, such as an enzyme linked immunosorbent assays (ELISA), a radioimmunoassay (RIA), or tissue
  • a conventional immunoassay such as an enzyme linked immunosorbent assays (ELISA), a radioimmunoassay (RIA), or tissue
  • Suitable detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, or acetylcholinesterase;
  • suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotnazinylamine fluorescein, dansyl chloride or phycoerythrin.
  • An example of a luminescent material is luminol and examples of suitable radioactive materials include
  • the binding proteins provided herein are capable of neutralizing the activity of their antigen targets both in vitro and in vivo. Accordingly, such binding proteins can be used to inhibit antigen activity, e.g., in a cell culture containing the antigens, in human subjects or in other mammalian subjects having the antigens with which a binding protein provided herein cross-reacts.
  • a method for reducing antigen activity in a subject suffering from a disease or disorder in which the antigen activity is detrimental is provided.
  • a binding protein provided herein can be administered to a human subject for therapeutic purposes.
  • a disorder in which antigen activity is detrimental is intended to include diseases and other disorders in which the presence of the antigen in a subject suffering from the disorder has been shown to be or is suspected of being either responsible for the pathophysiology of the disorder or a factor that contributes to a worsening of the disorder. Accordingly, a disorder in which antigen activity is detrimental is a disorder in which reduction of antigen activity is expected to alleviate the symptoms and/or progression of the disorder. Such disorders may be evidenced, for example, by an increase in the
  • concentration of the antigen in a biological fluid of a subject suffering from the disorder e.g., an increase in the concentration of antigen in serum, plasma, synovial fluid, etc., of the subject.
  • disorders that can be treated with the binding proteins provided herein include those disorders discussed below and in the section pertaining to pharmaceutical compositions comprising the binding proteins.
  • DVD binding proteins are useful as therapeutic agents to simultaneously block two different targets to enhance efficacy/safety and/or increase patient coverage.
  • DVD binding proteins provided herein can be employed for tissue-specific delivery (target a tissue marker and a disease mediator for enhanced local PK thus higher efficacy and/or lower toxicity), including intracellular delivery (targeting an internalizing receptor and an intracellular molecule), delivering to inside brain (targeting transferrin receptor and a CNS disease mediator for crossing the blood-brain barrier).
  • DVD binding protein can also serve as a carrier protein to deliver an antigen to a specific location via binding to a non-neutralizing epitope of that antigen and also to increase the half-life of the antigen.
  • DVD binding protein can be designed to either be physically linked to medical devices implanted into patients or target these medical devices (see Burke et al. (2006)Advanced Drug Deliv. Rev.
  • Binding protein molecules provided herein are useful as therapeutic molecules to treat various diseases, e.g., wherein the targets that are recognized by the binding proteins are detrimental. Such binding proteins may bind one or more targets involved in a specific disease. Binding to BBB receptors (e.g., TfR) has also been shown to enhance penetration of the blood brain barrier and thus is useful for delivering therapeutics to the brain. Without limiting the disclosure, further information on certain disease conditions is provided.
  • BBB receptors e.g., TfR
  • Neurodegenerative diseases are either chronic in which case they are usually age-dependent or acute (e.g., stroke, traumatic brain injury, spinal cord injury, etc.). They are characterized by progressive loss of neuronal functions (e.g., neuronal cell death, axon loss, neuritic dystrophy, demyelination), loss of mobility and loss of memory. These chronic neurodegenerative diseases represent a complex interaction between multiple cell types and mediators. Treatment strategies for such diseases are limited and mostly constitute either blocking inflammatory processes with non-specific anti-inflammatory agents (e.g., corticosteroids, COX inhibitors) or agents to prevent neuron loss and/or synaptic functions. These treatments fail to stop disease progression.
  • non-specific anti-inflammatory agents e.g., corticosteroids, COX inhibitors
  • binding protein molecules can allow for transport of therapeutics across the blood brain barrier.
  • these therapeutics bind one or more targets involved in chronic neurodegenerative diseases such as Alzheimer's disease.
  • the efficacy of binding protein molecules and its combination with other therapeutics can be validated in pre-clinical animal models such as the transgenic mice that over-express amyloid precursor protein or RAGE and develop Alzheimer's disease-like symptoms.
  • binding protein molecules can be constructed and tested for efficacy in the animal models and the best therapeutic binding protein can be selected for testing in human patients.
  • Binding protein molecules can also be employed for treatment of other neurodegenerative diseases such as Parkinson's disease.
  • Other pain related targets include CGRP, TNFa, RGMA, Substance P, Bradykinin, Nav1 .7, LPA, P2X3, and NGF.
  • spinal cord injury (SCI) is still a devastating condition and represents a medical indication characterized by a high medical need. Most spinal cord injuries are contusion or
  • compression injuries and the primary injury is usually followed by secondary injury mechanisms (inflammatory mediators e.g., cytokines and chemokines) that worsen the initial injury and result in significant enlargement of the lesion area, sometimes more than 10-fold.
  • secondary injury mechanisms inflammatory mediators e.g., cytokines and chemokines
  • binding protein molecules can be validated in pre-clinical animal models of spinal cord injury.
  • these binding protein molecules can be constructed and tested for efficacy in the animal models and the best therapeutic binding protein can be selected for testing in human patients.
  • antibodies do not cross the blood brain barrier (BBB) in an efficient and relevant manner.
  • BBB blood brain barrier
  • the BBB may be compromised and allows for increased penetration of binding proteins and antibodies into the brain.
  • carrier-mediated transporters such as glucose and amino acid carriers
  • receptor-mediated transcytosis- mediating cell structures/receptors at the vascular endothelium of the BBB, thus enabling trans-BBB transport of the binding protein.
  • Structures at the BBB enabling such transport include but are not limited to the insulin receptor, e.g., human insulin receptor (HIR), transferrin receptor, LRP family, IGFR, EPCR, EGFR, TNFR, Leptin receptor, M6PR, Neuronal nicotinic acetylcholine receptor, Lipoprotein receptor, AchR, DTr, Glutathione transporter, SR-B1 , MYOF, TFRC, ECE1.LDLR, PVR, CDC50A, SCARF1 , MRC1 , HLA- DRA, RAMP2, VLDLR, STAB1 , TLR9, CXCL16, NTRK1 , CD74, DPP4, TMEM30A,and RAGE.
  • HIR human insulin receptor
  • transferrin receptor LRP family
  • IGFR EPCR
  • EGFR TNFR
  • Leptin receptor M6PR
  • Neuronal nicotinic acetylcholine receptor Lipo
  • binding proteins also as shuttles to transport potential drugs into the CNS including low molecular weight drugs, nanoparticles and nucleic acids (Coloma et al. (2000) Pharm Res. 17(3):266-74; Boado et al. (2007) Bioconjug. Chem. 18(2):447-55).
  • a binding protein of the invention suitable for neurological use may bind at least one target antigen selected from the group consisting of Abeta; TNF-alpha; BACE1 ; IL-1 .beta; IGF1 ,2; IL-18; IL-6; RAGE; NGF; EGFR; CD-20 and RGMA.
  • a binding protein of the disclosure is suitable for anti-cancer use and binds at least one target antigen selected from the group consisting of CD-20; CD-19; CD-80; CD-22; CD-40; CD-3; HER-2; EGFR; IGF1 ,2; IGF1 R; RON; HGF; c-MET; VEGF; DLL4; NRP1 ; PLGF; and ErbB3.
  • target antigen selected from the group consisting of CD-20; CD-19; CD-80; CD-22; CD-40; CD-3; HER-2; EGFR; IGF1 ,2; IGF1 R; RON; HGF; c-MET; VEGF; DLL4; NRP1 ; PLGF; and ErbB3.
  • Pain can be classified as either acute or chronic. Acute pain can be caused by damage to tissue and generally has a sudden onset and a limited duration. Chronic pain tends to last longer than acute pain and is usually associated with a long-term illness. It is usually more resistant to treatment, and can be the defining characteristic of a disease (such as fibromyalgia). It can be the result of damaged tissue, but more often is attributed to nerve damage. Pain can also be classified by the kind of damage that causes it.
  • Nociceptive pain is pain caused by tissue damage, while neuropathic pain is pain caused by nerve damage. Nociceptive pain may be further divided into three different
  • sub-categories visceral, deep somatic, and superficial somatic pain.
  • pain examples include but are not limited to: acute pain, chronic pain, muscle pain, joint pain, chest pain, neck pain, shoulder pain, hip pain, abdominal pain, carpal tunnel syndrome, knee pain, back pain, myofascial pain syndrome, fibromyalgia, arthritic pain, headache (e.g., a migraine headache), Piriformis syndrome, whiplash, chronic muscle pain, nociceptive pain, visceral pain, deep somatic pain, superficial somatic pain, neuropathic pain, central pain syndrome, complex regional pain syndrome, diabetic peripheral neuropathy, pain associated with shingles, postherpetic neuralgia, neuralgia, trigeminal neuralgia, sciatica pain, arachnoiditis (spinal pain), central pain syndrome, phantom limb pain, phantom body pain, neuropathy, compartment syndrome, acute herpetic pain, post herpetic pain, causalgia pain, idiopathic pain, inflammatory pain, cancer pain, postoperative pain, interstitial cystitis
  • Neuropathic pain is a particular type of chronic pain that has a complex and variable etiology. It is frequently a chronic condition attributable to complete or partial transection of a nerve, trauma or injury to a nerve, nerve plexus or soft tissue, or other conditions, including cancer, AIDS and idiopathic causes. Neuropathic pain is
  • hyperalgesia lowered pain threshold and enhanced pain perception
  • allodynia pain from innocuous mechanical or thermal stimuli.
  • the condition is often progressive in nature. Because the hyperesthetic component of neuropathic pain does not respond to the same pharmaceutical interventions as does more generalized and acute forms of pain, development of effective long-term treatment modalities has been problematic.
  • Analgesia or the reduction of pain perception, can be attained by many methods including directly decreasing transmission along such nociceptive pathways by using for example opiates, and inhibiting release of neurotransmitters (See U.S. Patent Number 8,268,774, which is incorporated by reference, herein, in its entirety).
  • binding proteins or peptides described herein are effective delivery vehicles for an agent (e.g., therapeutic and diagnostic) for treatment of pain.
  • composition used for treatment of a subject comprises the binding protein or peptide herein; and at least one therapeutic agent.
  • the composition efficiently penetrates the BBB, and is effective for treatment and/or modulation of pain.
  • the binding protein is a bispecific molecule for example a bispecific DVD-lg as described herein.
  • the DVD-lg has at least one binding region that specifically binds a BBB receptor, antigen or target.
  • the BBB receptor, antigen or target comprises an insulin receptor, a transferrin receptor, a LRP, a melanocortin receptor, a nicotinic acetylcholine receptor, a VACM-1 receptor, a vascular endothelial growth factor, a glucocorticoid receptor, an ionotropic glutamate receptor, a M3 receptor, an aryl hydrocarbon receptor, a GLUT-1 , an inositol- 1 ,4,5-trisphosphate (IP3) receptor, a N-methyl-D-aspartate receptor, a S1 P1 , a P2Y receptor and a Receptor for Advanced Glycation Endproducts (RAGE) receptor.
  • an insulin receptor a transferrin receptor, a LRP, a melanocortin receptor, a nicotinic acetylcholine receptor, a VACM-1 receptor, a vascular endothelial growth factor, a
  • the pharmaceutical composition includes the binding protein or peptide, and a detectable agent.
  • the detectable agent comprises a detectable agent or imaging agent for analysis of the brain.
  • the detectable agent comprises a fluorescent agent, a colorimetric agent, an enzymatic agent, or a radioactive agent.
  • compositions comprising one or more binding proteins, either alone or in combination with prophylactic agents, therapeutic agents, and/or pharmaceutically acceptable carriers are provided.
  • the pharmaceutical compositions comprising binding proteins provided herein are for use in, but not limited to, diagnosing, detecting, or monitoring a disorder, in preventing, treating, managing, or ameliorating a disorder or one or more symptoms thereof, and/or in research.
  • the formulation of pharmaceutical compositions, either alone or in combination with prophylactic agents, therapeutic agents, and/or pharmaceutically acceptable carriers, is known to one skilled in the art (US Patent Publication No. 20090311253 A1 ).
  • Methods of administering a prophylactic or therapeutic agent provided herein include, but are not limited to, parenteral administration (e.g., intradermal, intramuscular, intraperitoneal, intravenous and subcutaneous), epidural administration, intratumoral administration, mucosal administration (e.g., intranasal and oral routes) and pulmonary administration (e.g., aerosolized compounds administered with an inhaler or nebulizer).
  • parenteral administration e.g., intradermal, intramuscular, intraperitoneal, intravenous and subcutaneous
  • epidural administration e.g., epidural administration
  • mucosal administration e.g., intranasal and oral routes
  • pulmonary administration e.g., aerosolized compounds administered with an inhaler or nebulizer
  • Dosage regimens may be adjusted to provide the optimum desired response (e.g., a therapeutic or prophylactic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
  • dosage unit form refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • An exemplary, non-limiting range for a therapeutically or prophylactically effective amount of a binding protein provided herein is 0.1 -20 mg/kg, for example, 1 -10 mg/kg. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
  • a binding protein provided herein also can also be administered with one or more additional medicaments or therapeutic agents useful in the treatment of various diseases, the additional agent being selected by the skilled artisan for its intended purpose.
  • the additional agent can be a therapeutic agent art-recognized as being useful to treat the disease or condition being treated by the antibody provided herein.
  • the combination can also include more than one additional agent, e.g., two or three additional agents.
  • the binding agent in various embodiments is administered with an agent that is a protein, a peptide, a carbohydrate, a drug, a small molecule, and a genetic material (e.g., DNA or RNA).
  • the agent is an imaging agent, a cytotoxic agent, an angiogenesis inhibitor, a kinase inhibitor, a co-stimulation molecule blocker, an adhesion molecule blocker, an anti-cytokine antibody or functional fragment thereof, methotrexate, cyclosporin, rapamycin, FK506, a detectable label or reporter, a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteriod, an anabolic
  • NSAID non
  • the additional agent in various embodiments is a therapeutic agent.
  • the therapeutic agent comprises budenoside, epidermal growth factor, a corticosteroid, cyclosporin, sulfasalazine, an aminosalicylate, 6-mercaptopurine, azathioprine, metronidazole, a lipoxygenase inhibitor, mesalamine, olsalazine, balsalazide, an antioxidant, a thromboxane inhibitor, an IL-1 receptor antagonist, an anti-IL-1 ⁇ mAbs, an anti-IL-6 or IL-6 receptor mAb, a growth factor, an elastase inhibitor, a pyridinyl-imidazole compound, an antibody specific against or an agonist of TNF, LT, IL-1 , IL-2, IL-6, IL-7, IL-8, IL-12, IL-13, IL-15, IL-16, IL-18, IL-
  • Combination therapy agents include, but are not limited to, antineoplastic agents, radiotherapy, chemotherapy such as DNA alkylating agents, cisplatin, carboplatin, anti-tubulin agents, paclitaxel, docetaxel, taxol, doxorubicin, gemcitabine, gemzar, anthracyclines, adriamycin, topoisomerase I inhibitors, topoisomerase I inhibitors, 5- fluorouracil (5-FU), leucovorin, irinotecan, receptor tyrosine kinase inhibitors (e.g. , erlotinib, gefitinib), COX-2 inhibitors (e.g. , celecoxib), kinase inhibitors, and siRNAs.
  • chemotherapy such as DNA alkylating agents, cisplatin, carboplatin, anti-tubulin agents, paclitaxel, docetaxel, taxol, doxorubicin, gemcitabine, gem
  • the disclosure herein also provides diagnostic applications including, but not limited to, diagnostic assay methods, diagnostic kits containing one or more binding proteins, and adaptation of the methods and kits for use in automated and/or semi- automated systems.
  • diagnostic applications including, but not limited to, diagnostic assay methods, diagnostic kits containing one or more binding proteins, and adaptation of the methods and kits for use in automated and/or semi- automated systems.
  • the methods, kits, and adaptations provided may be employed in the detection, monitoring, and/or treatment of a disease or disorder in an individual. This is further elucidated below.
  • the present disclosure also provides a method for determining the presence, amount or concentration of an analyte, or fragment thereof, in a test sample using at least one binding protein as described herein.
  • Any suitable assay as is known in the art can be used in the method. Examples include, but are not limited to, immunoassays and/or methods employing mass spectrometry.
  • Immunoassays provided by the present disclosure may include sandwich immunoassays, radioimmunoassay (RIA), enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), competitive-inhibition immunoassays, fluorescence polarization immunoassay (FPIA), enzyme multiplied immunoassay technique (EMIT), bioluminescence resonance energy transfer (BRET), and homogenous chemiluminescent assays, among others.
  • sandwich immunoassays radioimmunoassay (RIA), enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), competitive-inhibition immunoassays, fluorescence polarization immunoassay (FPIA), enzyme multiplied immunoassay technique (EMIT), bioluminescence resonance energy transfer (BRET), and homogenous chemiluminescent assays, among others.
  • RIA radioimmunoassay
  • EIA enzyme immunoassay
  • a chemiluminescent microparticle immunoassay in particular one employing the ARCHITECT® automated analyzer (Abbott Laboratories, Abbott Park, IL), is an example of an immunoassay.
  • Methods employing mass spectrometry are provided by the present disclosure and include, but are not limited to MALDI (matrix-assisted laser
  • kits for assaying a test sample for the presence, amount or concentration of an analyte, or fragment thereof, in a test sample comprises at least one component for assaying the test sample for the analyte, or fragment thereof, and instructions for assaying the test sample for the analyte, or fragment thereof.
  • the at least one component for assaying the test sample for the analyte, or fragment thereof can include a composition comprising a binding protein, as disclosed herein, and/or an anti-analyte binding protein (or a fragment, a variant, or a fragment of a variant thereof), which is optionally immobilized on a solid phase.
  • the kit may comprise a calibrator or control, which may comprise isolated or purified analyte.
  • the kit can comprise at least one component for assaying the test sample for an analyte by immunoassay and/or mass spectrometry.
  • the kit components including the analyte, binding protein, and/or anti-analyte binding protein, or fragments thereof, may be optionally labeled using any art-known detectable label.
  • the materials and methods for the creation provided for in the practice of the present disclosure would be known to one skilled in the art (US Patent Publication No. 2009-031 1253 A1 ).
  • kits or components thereof, as well as the method of determining the presence, amount or concentration of an analyte in a test sample by an assay, such as an immunoassay as described herein, can be adapted for use in a variety of automated and semi-automated systems (including those wherein the solid phase comprises a
  • microparticle as described, for example, in US Patent Nos. 5,089,424 and 5,006,309, and as commercially marketed, for example, by Abbott Laboratories (Abbott Park, IL) as ARCHITECT®.
  • kits and kit components can be employed in other formats, for example, on electrochemical or other hand-held or point-of-care assay systems.
  • the present disclosure is, for example, applicable to the commercial Abbott Point of Care (i-STAT®, Abbott Laboratories) electrochemical immunoassay system that performs sandwich immunoassays. Immunosensors and their methods of manufacture and operation in single-use test devices are described, for example in, US Patent No. 5,063,081 , 7,419,821 , and 7,682,833; and US Publication Nos.
  • DVD-lgbinding proteins using parent antibodies with known amino acid sequences were generated by synthesizing polynucleotide fragments encoding DVD binding protein variable heavy and DVD binding protein variable light chain sequences and cloning the fragments into a pHybE-D2 vector according to art known methods.
  • the DVD binding protein constructs were cloned into and expressed in 293 cells and purified according to art known methods. DVD VH and VL chains for the DVD binding proteins, as well as selected CDR sequences are provided below.
  • Table 2 List of Amino Acid Sequences of VH and VL Regions of Antibodies for Generating Binding Proteins, Including Multivalent Binding Proteins (CDRs highlighted)
  • Each murine variable heavy and variable light chain gene sequence was separately aligned against 44 human immunoglobulin germline variable heavy chain or 46 germline variable light chain sequences (derived from NCBI Ig Blast website at http://www.ncbi.nlm.nih.gov/igblast/retrieveig.html.) using Vector NTI software.
  • Humanization was based on amino acid sequence homology, CDR clusteranalysis, frequency of use among expressed human antibodies, and available information on the crystal structures of human antibodies. Taking into account possible effects on antibody binding, VH- VL pairing, and other factors, murine residues were mutated to human residues where murine and human framework residues are different, with a few exceptions. Additional humanization strategies were designed based on an analysis of human germline antibody sequences, or a subgroup thereof, that possessed a high degree of homology, i.e., sequence similarity, to the actual amino acid sequence of the murine antibody variable regions.
  • Homology modeling was used to identify residues unique to the murine antibody sequences that were predicted to be critical to the structure of the antibody combining site, the CDRs.
  • Homology modeling is a computational method whereby approximate three dimensional coordinates were generated for a protein.
  • the source of initial coordinates and guidance for their further refinement was a second protein, the reference protein, for which the three dimensional coordinates were known and the sequence of which was related to the sequence of the first protein.
  • the relationship among the sequences of the two proteins is used to generate a correspondence between the reference protein and the protein for which coordinates are desired, the target protein.
  • the primary sequences of the reference and target proteins are aligned with coordinates of identical portions of the two proteins transferred directly from the reference protein to the target protein.
  • Coordinates for mismatched portions of the two proteins are constructed from generic structural templates and energy refined to insure consistency with the already transferred model coordinates.
  • This computational protein structure may be further refined or employed directly in modeling studies. The quality of the model structure is determined by the accuracy of the contention that the reference and target proteins are related and the precision with which the sequence alignment is constructed.
  • a combination of BLAST searching and visual inspection is used to identify suitable reference structures. Sequence identity of 25% between the reference and target amino acid sequences is considered the minimum necessary to attempt a homology modeling exercise. Sequence alignments are constructed manually and model coordinates are generated with the program Jackal (see Petrey, D. et al. (2003) Proteins 53 (Suppl. 6): 430-435).
  • Example 3 Assays Used to Identify and Characterize Parent Antibodies and DVD-lgTM
  • Antibodies are diluted to 2.5 mg/mL with water and 20 ml_ is analyzed on a Shimadzu HPLC system using a TSK gel G3000 SWXL column (Tosoh Bioscience, cat# k5539-05k). Samples are eluted from the column with 21 1 mM sodium sulfate, 92 mM sodium phosphate, pH 7.0, at a flow rate of 0.3 mL/minutes.
  • the HPLC system operating conditions are the following:
  • Table 6 contains DVD-lgTM constructs expressed as percent monomer
  • DVD-lgTM s showed an excellent SEC profile with all DVD-lgTM showing >90% monomer. This DVD-lgTM profile is similar to that observed for parent antibodies.
  • ECL- MSD Cell-based Electrochemiluminescence-Meso Scale Discovery Assay
  • MSD Meso-scale Discovery
  • blocking buffer (30% FBS Serum (Hyclone) in PBS
  • the BIACORE assay (Biacore, Inc, Piscataway, NJ) was used to determine the affinity of antibodies or DVD-lgTM with kinetic measurements of on-rate and off-rate constants. Binding of antibodies or DVD-lgTM to a target antigen (for example, a purified recombinant target antigen) was determined by surface plasmon resonance-based measurements with a Biacore® 1000 or 3000 instrument (Biacore® AB, Uppsala, Sweden) using running HBS-EP (10 mM HEPES [pH 7.4], 150 mM NaCI, 3 mM EDTA, and 0.005% surfactant P20) at 25o C.
  • a target antigen for example, a purified recombinant target antigen
  • Rate constants are derived by making kinetic binding measurements at different antigen concentrations ranging from 10 - 200 nM.
  • mice were intravenously injected with anti-TfR variants, control IgG, anti-TfR containing DVD-lgTM s (20 mg/kg). After the indicated time, mice were perfused with D-PBS at a rate of 2 ml/min for 10 min. Brains were extracted and homogenized using Bullet Blender Blue (NextAdvance BBX24B) in 1 % NP-40 (Calbiochem) in PBS containing CompleteMini EDTA-free protease inhibitor cocktail tablets (Roche Diagnostics). Homogenized brain samples were rotated at 4 °C for 1 hour before spinning at 14,000 rpm for 20 min. Supernatant was isolated for brain antibody measurement. Whole blood was collected before perfusion in serum separator
  • microcontainer tubes (BDDiagnostics), allowed to clot for at least 30 min, and spun down at 5000g for 90 s. Supernatant was isolated for antibody measurement in serum.
  • Antibody or DVD-lgTM concentrations in mouse serum and brain samples were measured with an ECL-MSD assay.
  • MSD high bind 96-well plates (MSD cat # L11 XB-3) were coated with a F(ab')2 fragment of donkey anti-human lgG,Fc fragment-specific polyclonal antibody (Jackson ImmunoResearch) overnight at 4°C. Plates were blocked with 3% MSD Block buffer for 1 hour at 25 q C.
  • Each antibody or DVD-lgTM was used as an internal standard to quantify respective antibody or DVD-lgTM concentrations. Plates were washed with Wash Buffer and standards and samples diluted in 0.1 % serum containing 1 % MSD assay buffer were added and incubated for 2 hours at 25 °C. Bound antibody was detected with Goat anti-human Sulfo-TAG, MSD and read on MSD SECTOR Imager 6000. Concentrations were determined from the standard curve with a five-parameter nonlinear regression program using Excel Fit software.
  • mice were intravenously injected with an indicated antibody or DVD (20 mg/kg or as indicated). After the indicated time, mice were perfused as described above, and brains were fixed in 4% paraformaldehyde for 8 hours. Following fixation, tissues were processed through a graded series of alcohol to xylene and then paraffin embedded. For histological evaluation, 5- ⁇ brain sections were stained for the detection of anti-Human IgG.
  • the sections were blocked with 3% hydrogen peroxide for 30 minutes, washed with wash buffer then incubated for 8 minutes with Protease. Sections were blocked with a streptavidin and biotin blocking kit (Vector Laboratories, Burlingame, CA) for 8 minutes each, followed by Dako protein block for 30 minutes. Next, the sections were incubated for 1 hour at room temperature with a biotinylated-Donkey anti-human IgG (F(ab') fragmented antibody at 15 ⁇ g/ml followed by a streptavidin peroxidase reagent for 30 minutes. Following the streptavidin step the sections were reacted with DAB chromogen for 3 minutes to form a brown precipitate. The sections were then washed with water,
  • Image analysis A Semi-quantitative analysis of mean parenchymal intensity per section was developed. The cerebellum and cortex sections were analyzed
  • Example 6 Brain uptake of a DVD-lgTM via different routes of systemic administration.
  • mice were injected SC with indicated DVD-lgTM s at 20 mpk or 50 mpk and processed after 96 hours as described above. Another group was injected twice (at 0 and 48 hours) before processing after 96 hours as described. Brain serum concentration of 1 .58 +/- 0.20 nM was retained at 96 h after single 20 mpk SC administration. Brain and serum concentrations measured after 24h of IV injections of 20 mpk Tf R Abs or DVD2671 from different studies are shown for comparison in Table 10.
  • Example 8 DVD-lg generation and in vitro/in vivo screening
  • DVD-lg binding proteins were generated using recombinant methods, and were screened using in vitro and in vivo systems described herein ( Figure 4). Methods and systems described in previous examples (e.g., assays Used to Identify and Characterize Parent Antibodies and DVD-lgTM) were used in the following examples unless indicated otherwise.
  • DVD-lg binding proteins (approximately 10-40 DVDs) having domains that specifically bind a target and a TfR (target/TfR DVD) were designed and expressed at a concentration of about five milligrams (mg) using methods and material described herein.
  • In vitro analysis was performed on the target/TfR DVD-lgs using a cell-based TfR binding assay (low affinity required) and a cell-based bioassay target (high potency required). The target/TfR DVD-lgs were then analyzed and compared in an in vivo biodistribution/brain penetration system using murine subjects.
  • Specimens/samples e.g., cells and tissues
  • Specimens/samples were analyzed to determine the presence of the target/TfR DVD-lg in the subjects.
  • a portion of the specimen/samples were analyzed to determine concentration of target/TfR DVD in the brain, and to calculate percent injected dose per gram tissue (%ID/g).
  • Another portion of the specimens/samples were analyzed immunohistochemically to determine localization of the target/TfR DVD-lgs in the brain.
  • DVD-lgTM design could be optimized by again designing and expressing target/TfR DVDs and analyzing using the assays and methods described above (e.g., in vitro activity and in vivo biodistribution/brain penetration).
  • the target/TfR DVD Igs having been tested and/or optimized were then expressed in a large scale.
  • In vitro quality control (QC) methods and conditions were performed on the material used in efficacy studies.
  • the resulting DVDs were then used in a multi-dose pharmacokinetics (PK) study over a period of 24-96 hours.
  • PK pharmacokinetics
  • Figure 5 shows an exemplary DVD-lg binding protein.
  • immunoglobulin includes at least one heavy chain variable domain that specifically binds a BBB antigen (anti-BBB antigen), and at least one heavy chain variable domain that specifically binds target X.
  • anti-BBB antigen antigen-BBB antigen
  • DVD-lgs engineered and analyzed by these methods efficiently penetrate the BBB and bind to target on or in the brain.
  • Example 9 In vivo tissue distribution analysis of DVD-lgs [0474] Analysis of in vivo tissue distribution for antibodies or a DVD-lgs was performed as shown in Figure 6. At day 0, murine subjects were intravenously injected or intraperitoneally injected with 5-50 mg/kg (mpk) of a DVD-lgTM, or a control human IgGl k antibody. The DVD-lgTM contained a binding region specific for a BBB antigen and another binding region specific for a target. The subjects were injected at hour zero, one hour, twenty four hours or 96 hours. Subjects were sacrificed at the indicated time using a mixture of ketamine and xylazine.
  • Serum from each subject was collected and analyzed for concentration of control antibody or DVD-lgTM using MSD-ESL assays.
  • the assays used plates coated with F(ab')2 fragment of donkey anti-human IgG which specifically bound both the human IgGl k antibody and a DVD Ig. Plates were then contacted with a full length anti-human Ig having a sulfo detection tag, and presence of antibody was detected.
  • tissues were treated with paraformaldehyde and then embedded in paraffin.
  • the embedded material was stained for the detection of anti-Human IgG using a biotinylated donkey anti-human IgG (H+L).
  • H+L biotinylated donkey anti-human IgG
  • DAB diaminobenzidine
  • Example 10 Analysis of anti-mouse TfR(AB221 ) antibody and humanized variants
  • Examples herein analyzed the binding and BBB penetration characteristics of antibody AB221 (lgG2a antibody that specifically recognizes murine TfR) and humanized variants (Table 12). Presence of TfR antibody AB221 and its humanized variants were analyzed using assays and methods described in Figure 6. Data show higher presence of TfR antibody AB221 and its humanized variants in the serum and brain compared to the human isotype lgG1 control. Immunohistochemical staining showed greater staining for AB221 anti-mouse TfR antibody in the blood vessels and Purkinje cells in the cerebellum compared to control i so type human lgG1 control ( Figure 2).
  • Example 11 Elevated levels of DVD-lgs detected by two orthogonal methods (IHC and MSD-ECL) and ability to transport across the BBB after a therapeutic dosing
  • the half maximal inhibitory concentration (iC 50 ) is a measure of the effectiveness of a compound in inhibiting biological or biochemical function. It was observed that the DVD-Igs containing a portion that specifically bound TfR more effectively inhibited TfR and were present at a higher concentration in the brain than control DVD-lgTM (Table 13). The MSD-ECL and immunohistochemicai data demonstrate that the DVD-Igs were effectively transported across the BBB after therapeutic dosing.
  • Figure 3 is an exemplary micrograph showing that the DVD-Igs were more localized in the parenchymal tissues and neuronal cells of the brain than subjects administered the control (non-TfR) DVD-lg.
  • Table 14 contains a list of TNF/TfR DVD-Igs.
  • the criteria for selection of DVDs for subsequent pain efficacy analysis included data showing iow TfR binding affinity, as based on the data in Example 10 lower affinity TfR antibodies in the outer position of a DVD-lg more efficiently penetrate the BBB. DVDs were further selected based on the highest concentration in the serum and brain, penetration through the BBB, and highest anti-TNF potency.
  • TNF antibody 8C1 1 strongly bound and inhibited TNF.
  • the anti-TNF antibody 8C1 1 has the following binding VH and VL regions:
  • RGMA(AE12-1 )-GS-Tf R(AB403) and TfR(AB405)-SL-RGMA(AE12-1 ) were scaled up for efficacy.
  • Monoclonal antibody AB221 was used in examples herein and data using this antibody were compared to data using antibody 8C1 1.
  • the six CDRs for antibody 8C1 1 (CDR-L1 , -L2, and -L3 of light chain and CDR-H1 , -H2, and -H3 of heavy chain are highlighted bo Ided portions in SEQ ID NOs: 162-163 above.
  • the CDRs of the heavy chain are DYNMN (SEQ ID NO: 164), VINPNYGSSTYNQKFKG (SEQ ID NO: 165), and
  • KWGQLGRGFFD (SEQ ID NO: 166).
  • the CDRs of the light chain are RASSSVSYMH (SEQ ID NO: 167), ATSNLAS (SEQ ID NO: 168), and QQWSSSPLT (SEQ ID NO: 169)
  • Example 13 Brain concentration and location analysis of selected DVD-lgs
  • DVD-lgs having a portion with antibody AB221 or humanized variant AB405 were constructed and analyzed in examples herein. Control DVD-lgs were also analyzed.
  • 8C1 1 -hFc DVD-lg contained 8C1 1 antibody, which specifically binds TNF, and an antibody that binds the Fc portion of human Immunoglobulin G (hFc).
  • the TNF-GS- AB221 DVD-lg contained an antibody that binds TNF, a GS linker and monoclonal antibody AB221 (lgG2a) that specifically recognizes murine TfR.
  • the TfR(AB405)-SL-TNF DVD-lg contained AB405 (a humanized variant of AB221 antibody), a SL linker, and an antibody that binds TNF.
  • Exemplary tissue staining data is shown in Figure7. Table 15 shows the concentration and localization data in the brain for subjects administered TfR(AB405)-SL-TNF DVD-lg, TNF-GS-AB221 DVD, 8C11 -hFc DVD-lg, human IgG DVD control.
  • Example 14 Intrathecal administration of TNF/TfR DVD-lgs crossed the BBB and effectively reduced pain
  • Examples herein analyzed the effectiveness of intrathecal administration of TNF/TfR DVD-lgs in a pain efficacy model.
  • Partial nerve injuries such as unilateral loose ligation or chronic constriction injury (CCI) of the sciatic nerve, result in the animal persistently holding the ipsilateral hindpaw in a guarded position.
  • CCI chronic constriction injury
  • the allodynia and hyperalgesia can persist for hours or days.
  • the Bennett model as it is known involves a surgery to induce a nerve injury and is a well- known pharmacokinetics (PK) and pain efficacy model.
  • PK pharmacokinetics
  • BALB/c murine subjects underwent a Bennett surgery and were intrathecally injected daily with either control IgG specific for mouse Fc (48 ⁇ g/10 ⁇ dose per injection); 8C1 1 -GS-AB221 DVD-lg (anti-TNFa/ anti-Tf R; 55 ⁇ g/10 ⁇ dose per injection); or morphine (10 ⁇ g/10 ⁇ dose per injection). Subjects were injected daily. Mechanical allodynia was assessed in the above Bennett model 120 minutes post-injection administration at day 1 and day 5 ( Figure 8).
  • the amount of 8C1 1 -GS-AB221 DVD-lg present in the brain following an intravenous injection was observed to be similar (16 nM; Table 15), which shows tha efficiacious amounts were obtained in the brain by 20 mpK intravenous injection.
  • Example 15 Intravenous administration of TNF/TfR DVD-lgs was effective to cross the BBB and reduce pain
  • Examples herein analyzed the effectiveness of intravenous administration of TNF/TfR DVD-lgs in the Bennett PK/pain efficacy model described above.
  • control IgG specific for mouse Fc 48 ⁇ g/10 ⁇ dose per injection
  • 8C1 1 -GS-AB221 DVD anti-TNFa/ anti-TfR; 55 ⁇ /10 ⁇ dose per injection
  • an acute post-operation dose of gabapentin 10 ⁇ g/10 ⁇ dose per injection.
  • Subjects were injected daily (20 mg/kg). Mechanical allodynia was assessed in the above Bennett model 120 minutes post-injection at day 1 and at day 5.
  • Example 16 RGMA-TfR DVD-lgs in a multiple sclerosis model
  • Repulsive guidance molecule A is a repulsive guidance molecule for retinal axons. After induced spinal cord injury RGMA accumulates in the scar tissue around the lesion, and presence of RGMA may be an inhibitor of axonal outgrowth.
  • Table 14 lists the RGMA-Tfr DVD-lgs that were analyzed for suitability for a model for MS.
  • the DVD-IGs were engineered to have the anti-BBB antigen portion or anti- target portion in the outer position (N-terminus) or the inner position (C-terminus).
  • Examples herein show that depending on the position of the anti-BBB epithelium antigen portion, one would either select a lower affinity antibody (outer position) or a higher affinity antibody (inner position).
  • the criteria for selection of DVD-lgs for use in the MS efficacy model was low TfR binding affinity, the highest anti-RGMA potency, the highest serum and brain concentrations, and greatest BBB penetration.
  • DVD-lg TfR(AB405)-SL- RGMA(AE12-1 ) and DVD-lg TfR( AB405)-LS-RGMA(AE12-1 ) were selected, expressed in a larger scale and analyzed for efficacy in a MS model described herein.
  • Alternativey, using an anti-BBB antigen antibody in the inner position one might have selected a DVD-lg with higherTfR binding affinity, the highest anti-RGMA potency, the highest serum and brain concentrations, and greatest BBB penetration.
  • RGMA-JL3-VH (AE12-1 ) (SEQ ID NO: 170) is
  • RGMA-JL3-VL (AE12-1 ) ) (SEQ ID NO: 171 ) is
  • CDR-L1 , -L2, and -L3 of light chain and CDR-H1 , -H2, and - H3 of heavy chain are highlighted/bolded portions in SEQ ID NOs: 170-171 above.
  • the CDRs of the heavy chain are SHGIS (SEQ ID NO: 172), WISPYSGNTNYAQKLQ (SEQ ID NO: 173), and VGSGPYYYMDV (SEQ ID NO: 174).
  • the CDRs of the light chain are TGTSSSVGDSIYVS (SEQ ID NO: 175), DVTKRPS (SEQ ID NO: 176), and CSYAGTDTL (SEQ ID NO: 177). See U.S. patent publication 2010/0074900 published March 25, 2010 and international publication WO/2013/1 12922 published August 1 , 2013, each of which is incorporated by reference herein in its entirety.
  • Figure 10 is an exemplary micrograph of stained brain tissue from subjects administered either: 40 mpk of RGMA (AE12-1 )-hFc at 24 hours; 30 mpk human IgG control; 20 mpk of RGMA (AE12-1 )-GS-AB403 DVD-lg, or 30 mpk of RGMA (AE12-1 )-GS- AB403 DVD-lg.
  • Data show effective staining of brain tissues from subjects contacted with RGMA (AE12-1 )-GS-AB403 DVD-lg, indicating that the DVD-lg effectively crossed the BBB and bound to RGMA on neuronal cells/tissue in the brain.
  • Bapineuzumab is a humanized monoclonal antibody (Mab) that targets the neurotoxic amyloid-beta peptide.
  • Amyloid-beta ( ⁇ ) is an early biomarker of Alzheimer's disease and other neurodegenerative pathologies.
  • Murine antibody 3D6 is the parent of the humanized monoclonal antibody Bapineuzumab,
  • DVD-lgs were designed and constructed that contained a portion that specifically bound to ⁇ , and another portion that bound TfR. Examples of DVD Igs and components that bind ⁇ are shown in Tables 2-4. Table 16 shows a list of ⁇ /TfR DVD- lgs that were engineered and analyzed in assays and a model system for: binding to TfR and ⁇ , for concentration in serum and the brain, and for IHC staining in the parenchyma and neurons.
  • Example 18 TNF/TfR DVD-Igs concentration and localization in the serum and brain
  • Tf R(AB405)-SL-TNF DVD-Igs administered to subjects in a PK study described above. Subjects were administered different doses (single or multiple doses of 20-40mpk) of TfPi(AB405)-SL-TNF DVD-Igs either subcutaneously (SC), intravenously (IV), or intraperitoneally (IP).
  • SC subcutaneously
  • IV intravenously
  • IP intraperitoneally
  • Example 19 TfR/RGMA DVD-lg concentration and localization in the serum and brain
  • Examples herein analyzed the concentration and localization of AB405-SL- RGMA DVD-Igs administered to male BALB/c murine subjects in a PK study described above. Subjects were administered AB405-SL-RGMA DVD-Igs at different doses (single or multiple doses of 20-40mpk) either subcutaneously (SC), intravenously (IV), or intraperitoneally (IP). Table 18 shows concentration and localization data in serum and the brain for subjects administered AB405-SL-RGMA DVD-Igs. Table 18. AB405-SL-RG A DVD-lgs concentration and localization in serum and the
  • DVD-lgs described herein in Examples were detected by IHC staining in parenchyma and neuronal cells in two hours following a single systemic injection (20mpk, intravenous). Increased brain uptake was observed at 24 hours after injection. Further, the DVD-lgs were retained in the brain for at least about 96 hours following a single intravenous injection of 50 mpk. The DVD-lgs accumulated in the brain by using multiple injections, for example using two 20 mpk intravenous injections. In fact, similar brain uptake data was observed with either intravenous.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des protéines de liaison multivalentes et multi-spécifiques génétiquement modifiées capables de pénétrer la barrière hémato-encéphalique (BBB), ainsi que des procédés de fabrication et des utilisations dans la prévention, le diagnostic et/ou le traitement d'une maladie.
EP13812312.0A 2012-12-04 2013-12-04 Protéines de liaison à double spécificité pénétrant la barrière hémato-encéphalique (bbb) Withdrawn EP2928919A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261733252P 2012-12-04 2012-12-04
US201361792163P 2013-03-15 2013-03-15
PCT/US2013/073114 WO2014089209A2 (fr) 2012-12-04 2013-12-04 Protéines de liaison à double spécificité pénétrant la barrière hémato-encéphalique (bbb)

Publications (1)

Publication Number Publication Date
EP2928919A2 true EP2928919A2 (fr) 2015-10-14

Family

ID=49881016

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13812312.0A Withdrawn EP2928919A2 (fr) 2012-12-04 2013-12-04 Protéines de liaison à double spécificité pénétrant la barrière hémato-encéphalique (bbb)

Country Status (7)

Country Link
US (1) US20140212423A1 (fr)
EP (1) EP2928919A2 (fr)
JP (1) JP2016501881A (fr)
AU (1) AU2013355324A1 (fr)
BR (1) BR112015012014A2 (fr)
CA (1) CA2890455A1 (fr)
WO (1) WO2014089209A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
IL297229A (en) * 2012-01-27 2022-12-01 Abbvie Inc The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
WO2015191783A2 (fr) 2014-06-10 2015-12-17 Abbvie Inc. Biomarqueurs des maladies inflammatoires et leurs procédés d'utilisation
WO2015191934A2 (fr) * 2014-06-11 2015-12-17 Abbvie Inc. Barrière hémato-encéphalique pénétrant des protéines de liaison spécifiques doubles pour le traitement de maladies cérébrales et neurologiques
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
EP3250595B1 (fr) * 2015-01-29 2024-04-24 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Molécules d'anticorps et systèmes d'administration peptidiques destinés à être utilisés dans la maladie d'alzheimer et autres troubles apparentés
WO2016160976A2 (fr) * 2015-03-30 2016-10-06 Abbvie Inc. Protéines de liaison au tnf monovalentes
PL3292149T3 (pl) 2015-05-04 2022-03-21 Cytomx Therapeutics, Inc. Aktywowalne przeciwciała anty-cd71 i sposoby ich stosowania
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
LT3313879T (lt) 2015-06-24 2022-03-25 F. Hoffmann-La Roche Ag Antikūnai prieš transferino receptorių su pritaikytu giminingumu
US11571480B2 (en) 2015-08-11 2023-02-07 Coherent Biopharma I, Limited Multi-ligand drug conjugates and uses thereof
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TWI819458B (zh) 2015-10-02 2023-10-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
JP2019517480A (ja) * 2016-06-01 2019-06-24 アッヴィ・インコーポレイテッド 脊髄損傷及び疼痛を処置するための抗ＲＧＭａ（Ｒｅｐｕｌｓｉｖｅ Ｇｕｉｄａｎｃｅ Ｍｏｌｅｃｕｌｅ Ａ）アンタゴニスト抗体
EP3583120B1 (fr) 2017-02-17 2022-10-05 Denali Therapeutics Inc. Polypeptides de liaison au récepteur de transferrine modifiés
WO2018165619A1 (fr) 2017-03-09 2018-09-13 Cytomx Therapeutics, Inc. Anticorps de cd147, anticorps activables de cd147 et procédés associés de fabrication et d'utilisation
WO2019173771A1 (fr) 2018-03-09 2019-09-12 Cytomx Therapeutics, Inc. Anticorps activables de cd147 et procédés de fabrication et d'utilisation associés
CA3141815A1 (fr) * 2018-08-22 2020-02-27 Denali Therapeutics Inc. Polypeptides anti-her2 et leurs methodes d'utilisation
WO2020102577A1 (fr) * 2018-11-16 2020-05-22 The Brigham And Women's Hospital, Inc. Anticorps bloquant la signalisation notch médiée par dll4
US20220023434A1 (en) 2018-12-19 2022-01-27 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods
EP3947452A4 (fr) * 2019-03-29 2023-05-03 Lankenau Institute for Medical Research Anticorps anti-récepteur nmda et procédés d'utilisation
CN114650844A (zh) 2019-09-23 2022-06-21 西托姆克斯治疗公司 抗cd47抗体、可活化抗cd47抗体及其使用方法
CA3165846A1 (fr) 2019-12-23 2021-07-01 Denali Therapeutics Inc. Variants de la progranuline
CA3179911A1 (fr) * 2020-04-08 2021-10-14 Janssen Biotech, Inc. Compositions et methodes d'administration a la barriere hemato-encephalique

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2128208A (en) 1937-02-27 1938-08-23 Du Pont Alkoxy derivatives of methacrylic acid esters and method of producing them
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
CA2069530A1 (fr) 1991-06-03 1992-12-04 Cass J. Grandone Trousse de reactifs pour dosages immunologiques
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
DE60137421D1 (de) 2000-06-29 2009-03-05 Abbott Lab Antikörper mit zwei spezifizitäten und verfahren zur deren herstellung und verwendung
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
CA2872136C (fr) 2002-07-18 2017-06-20 Merus B.V. Production par recombinaison de melanges d'anticorps
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US7268109B2 (en) 2003-10-02 2007-09-11 Elan Pharmaceuticals, Inc. Method for reducing pain
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ600979A (en) 2008-01-15 2014-01-31 Abbott Lab Improved mammalian expression vectors and uses thereof
KR20110014607A (ko) 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2297208A4 (fr) 2008-06-03 2012-07-11 Abbott Lab Immunoglobulines à double domaine variable et leurs utilisations
CA2729949A1 (fr) 2008-07-08 2010-01-14 Abbott Laboratories Immunoglobulines a double domaine variable de prostaglandine e2 et leurs utilisations
US20100077498A1 (en) * 2008-09-11 2010-03-25 Pardridge William M Compositions and methods for blood-brain barrier delivery in the mouse
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TWI689314B (zh) * 2010-11-30 2020-04-01 建南德克公司 低親和力血腦障壁受體抗體及其用途
EP2654792A4 (fr) 2010-12-22 2016-05-11 Abbvie Inc Protéines de liaison à une demi-immunoglobuline et leurs utilisations
IL297229A (en) 2012-01-27 2022-12-01 Abbvie Inc The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2014089209A2 *

Also Published As

Publication number Publication date
WO2014089209A2 (fr) 2014-06-12
JP2016501881A (ja) 2016-01-21
CA2890455A1 (fr) 2014-06-12
AU2013355324A1 (en) 2015-05-21
WO2014089209A3 (fr) 2014-08-21
BR112015012014A2 (pt) 2017-07-11
US20140212423A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
US20140212423A1 (en) Blood-brain barrier penetrating dual specific binding proteins
US9469689B2 (en) Therapeutic DLL4 binding proteins
US9469688B2 (en) Therapeutic DLL4 binding proteins
JP7257364B2 (ja) 抗ｃｄ１３７抗体
US20160002343A1 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
JP2020504171A (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
TW201333033A (zh) 雙可變域免疫球蛋白及其用途
JP7257971B6 (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
KR20150131360A (ko) ＴＮＦα에 대해 지시된 이원 특이적 결합 단백질
TW201323441A (zh) 抗ｔｎｆ之雙特異性免疫結合物
JP2016510319A (ja) 多価結合タンパク質組成物
TW201333035A (zh) 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
US10093733B2 (en) LRP-8 binding dual variable domain immunoglobulin proteins
TW201904999A (zh) 抗gitr抗體、其抗原結合片段及其醫藥用途
JP2020524988A (ja) 抗ｒｏｂｏ２抗体、組成物、方法、およびその使用
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150622

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

17Q First examination report despatched

Effective date: 20170512

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170923